microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft health care professionals information  alunbrig brigatinib for healthcare professionals this site is intended for us healthcare professionals only now approved introducing alunbrig™—a new treatment for patients with anaplastic lymphoma kinase alkpositive metastatic nonsmall cell lung cancer nsclc who have progressed on or are intolerant to crizotinib this indication is approved under accelerated approval based on tumor response rate and duration of response continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial   in the news learn more about the fda approval of alunbrig view press release patient support alunbrig point can support your patients throughout the course of their therapy access a patient access specialist can work with your patient and your office to conduct a benefits investigation and provide you both with details on your patients drug coverage and options afford regardless of your patients insurance status alunbrig point can help identify an array of financial assistance programs for which they may be eligible assist alunbrig point is committed to supporting your patients throughout their treatment by offering a wide range of services to get them the information they need and assist with daytoday concerns associated with their treatment find out more important resources for your practice download dosing guide stay connected stay informed about alunbrig—sign up to be notified about product and news updates required fields first name please enter your first name last name please enter your last name email address please enter your email please select your specialty select oncology radiology internal medicine other physician nursing pharmacy other hcp please select your specialty i would like to receive updates about alunbrig using the contact information i provided above check this box to confirm that you agree to takeda’s privacy policy and terms and conditions and that takeda or companies working with takeda may send you information about lung cancer takeda products and services and other healthrelated topics using the contact information you provided above please confirm that you accept our privacy policy and terms and conditions submit you have successfully registered thank you for registering you will hear from us when we have updates alunbrig product information overviewalunbrig dosage andadministration efficacyand safety summary please read full prescribing information for alunbrig important safety information warnings and precautions interstitial lung disease ildpneumonitis severe lifethreatening and fatal pulmonary adverse reactions consistent with interstitial lung disease ildpneumonitis have occurred with alunbrig in trial alta alta ildpneumonitis occurred in  of patients in the  mg group  mg once daily and  of patients in the → mg group  mg once daily with day leadin at  mg once daily adverse reactions consistent with possible ildpneumonitis occurred early within  days of initiation of alunbrig median onset was  days in  of patients with grade  to  reactions occurring in  monitor for new or worsening respiratory symptoms eg dyspnea cough etc particularly during the first week of initiating alunbrig withhold alunbrig in any patient with new or worsening respiratory symptoms and promptly evaluate for ildpneumonitis or other causes of respiratory symptoms eg pulmonary embolism tumor progression and infectious pneumonia for grade  or  ildpneumonitis either resume alunbrig with dose reduction after recovery to baseline or permanently discontinue alunbrig permanently discontinue alunbrig for grade  or  ildpneumonitis or recurrence of grade  or  ildpneumonitis hypertension in alta hypertension was reported in  of patients in the  mg group who received alunbrig and  of patients in the → mg group grade  hypertension occurred in  of patients overall control blood pressure prior to treatment with alunbrig monitor blood pressure after  weeks and at least monthly thereafter during treatment with alunbrig withhold alunbrig for grade  hypertension despite optimal antihypertensive therapy upon resolution or improvement to grade  severity resume alunbrig at a reduced dose consider permanent discontinuation of treatment with alunbrig for grade  hypertension or recurrence of grade  hypertension use caution when administering alunbrig in combination with antihypertensive agents that cause bradycardia bradycardia bradycardia can occur with alunbrig in alta heart rates less than  beats per minute bpm occurred in  of patients in the  mg group and  of patients in the → mg group grade  bradycardia occurred in   patient in the  mg group monitor heart rate and blood pressure during treatment with alunbrig monitor patients more frequently if concomitant use of drug known to cause bradycardia cannot be avoided for symptomatic bradycardia withhold alunbrig and review concomitant medications for those known to cause bradycardia if a concomitant medication known to cause bradycardia is identified and discontinued or dose adjusted resume alunbrig at the same dose following resolution of symptomatic bradycardia otherwise reduce the dose of alunbrig following resolution of symptomatic bradycardia discontinue alunbrig for lifethreatening bradycardia if no contributing concomitant medication is identified visual disturbance in alta adverse reactions leading to visual disturbance including blurred vision diplopia and reduced visual acuity were reported in  of patients treated with alunbrig in the  mg group and  of patients in the → mg group grade  macular edema and cataract occurred in one patient each in the → mg group advise patients to report any visual symptoms withhold alunbrig and obtain an ophthalmologic evaluation in patients with new or worsening visual symptoms of grade  or greater severity upon recovery of grade  or grade  visual disturbances to grade  severity or baseline resume alunbrig at a reduced dose permanently discontinue treatment with alunbrig for grade  visual disturbances creatine phosphokinase cpk elevation in alta creatine phosphokinase cpk elevation occurred in  of patients receiving alunbrig in the  mg group and  of patients in the  mg→ mg group the incidence of grade  cpk elevation was  in the  mg group and  in the → mg group dose reduction for cpk elevation occurred in  of patients in the  mg group and  in the → mg group advise patients to report any unexplained muscle pain tenderness or weakness monitor cpk levels during alunbrig treatment withhold alunbrig for grade  or  cpk elevation upon resolution or recovery to grade  or baseline resume alunbrig at the same dose or at a reduced dose pancreatic enzyme elevation in alta amylase elevation occurred in  of patients in the  mg group and  of patients in the → mg group lipase elevations occurred in  of patients in the  mg group and  of patients in the → mg group grade  or  amylase elevation occurred in  of patients in the  mg group and  of patients in the → mg group grade  or  lipase elevation occurred in  of patients in the  mg group and  of patients in the → mg group monitor lipase and amylase during treatment with alunbrig withhold alunbrig for grade  or  pancreatic enzyme elevation upon resolution or recovery to grade  or baseline resume alunbrig at the same dose or at a reduced dose hyperglycemia in alta  of patients who received alunbrig experienced new or worsening hyperglycemia grade  hyperglycemia based on laboratory assessment of serum fasting glucose levels occurred in  of patients two of   patients with diabetes or glucose intolerance at baseline required initiation of insulin while receiving alunbrig assess fasting serum glucose prior to initiation of alunbrig and monitor periodically thereafter initiate or optimize antihyperglycemic medications as needed if adequate hyperglycemic control cannot be achieved with optimal medical management withhold alunbrig until adequate hyperglycemic control is achieved and consider reducing the dose of alunbrig or permanently discontinuing alunbrig embryofetal toxicity based on its mechanism of action and findings in animals alunbrig can cause fetal harm when administered to pregnant women there are no clinical data on the use of alunbrig in pregnant women advise pregnant women of the potential risk to a fetus advise females of reproductive potential to use effective nonhormonal contraception during treatment with alunbrig and for at least  months following the final dose advise males with female partners of reproductive potential to use effective contraception during treatment and for at least  months after the last dose of alunbrig adverse reactions serious adverse reactions occurred in  of patients in the  mg group and  of patients in the → mg group the most common serious adverse reactions were pneumonia  overall  in the  mg group and  in the → mg group and ildpneumonitis  overall  in the  mg group and  in the → mg group fatal adverse reactions occurred in  of patients and consisted of pneumonia  patients sudden death dyspnea respiratory failure pulmonary embolism bacterial meningitis and urosepsis  patient each the most common adverse reactions ≥ in the  mg group were nausea  fatigue  headache  and dyspnea  and in the → mg group were nausea  diarrhea  fatigue  cough  and headache  drug interactions cypa inhibitors avoid concomitant use of alunbrig with strong cypa inhibitors avoid grapefruit or grapefruit juice as it may also increase plasma concentrations of brigatinib if concomitant use of a strong cypa inhibitor is unavoidable reduce the dose of alunbrig cypa inducers avoid concomitant use of alunbrig with strong cypa inducers cypa substrates coadministration of alunbrig with cypa substrates including hormonal contraceptives can result in decreased concentrations and loss of efficacy of cypa substrates use in specific populations pregnancy alunbrig can cause fetal harm advise females of reproductive potential of the potential risk to a fetus lactation advise lactating women not to breastfeed during treatment with alunbrig and for  week following the final dose females and males of reproductive potential contraception advise females of reproductive potential to use effective nonhormonal contraception during treatment with alunbrig and for at least  months after the final dose advise males with female partners of reproductive potential to use effective contraception during treatment with alunbrig and for at least  months after the final dose infertility alunbrig may cause reduced fertility in males pediatric use the safety and efficacy of alunbrig in pediatric patients have not been established geriatric use clinical studies of alunbrig did not include sufficient numbers of patients aged  years and older to determine whether they respond differently from younger patients of the  patients in alta  were  years and  were  years or older no clinically relevant differences in safety or efficacy were observed between patients ≥ and younger patients hepatic or renal impairment no dose adjustment is recommended for patients with mild hepatic impairment or mild or moderate renal impairment the safety of alunbrig in patients with moderate or severe hepatic impairment or severe renal impairment has not been studied you may report side effects to the fda at fda or wwwfdagovmedwatch you may also report side effects directly to takeda oncology at apoint  or medinfoariadcom please read full prescribing information for alunbrig   you are now leaving alunbrigcom the official site for alunbrig™ brigatinib this link will take you to the corporate takeda oncology website continue cancel you are now leaving alunbrigcom the official site for alunbrig™ brigatinib this link will take you to the alunbrig point™ website continue cancel you are now leaving alunbrigcom the official site for alunbrig™ brigatinib this link will take you to the fda website continue cancel the site you are about to enter is intended for us healthcare professionals only please confirm that you are a us healthcare professional yes i confirm that i am a us healthcare professional cancel health care professionals information  alunbrig brigatinib for healthcare professionals this site is intended for us healthcare professionals only now approved introducing alunbrig™—a new treatment for patients with anaplastic lymphoma kinase alkpositive metastatic nonsmall cell lung cancer nsclc who have progressed on or are intolerant to crizotinib this indication is approved under accelerated approval based on tumor response rate and duration of response continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial   in the news learn more about the fda approval of alunbrig view press release patient support alunbrig point can support your patients throughout the course of their therapy access a patient access specialist can work with your patient and your office to conduct a benefits investigation and provide you both with details on your patients drug coverage and options afford regardless of your patients insurance status alunbrig point can help identify an array of financial assistance programs for which they may be eligible assist alunbrig point is committed to supporting your patients throughout their treatment by offering a wide range of services to get them the information they need and assist with daytoday concerns associated with their treatment find out more important resources for your practice download dosing guide stay connected stay informed about alunbrig—sign up to be notified about product and news updates required fields first name please enter your first name last name please enter your last name email address please enter your email please select your specialty select oncology radiology internal medicine other physician nursing pharmacy other hcp please select your specialty i would like to receive updates about alunbrig using the contact information i provided above check this box to confirm that you agree to takeda’s privacy policy and terms and conditions and that takeda or companies working with takeda may send you information about lung cancer takeda products and services and other healthrelated topics using the contact information you provided above please confirm that you accept our privacy policy and terms and conditions submit you have successfully registered thank you for registering you will hear from us when we have updates alunbrig product information overviewalunbrig dosage andadministration efficacyand safety summary please read full prescribing information for alunbrig important safety information warnings and precautions interstitial lung disease ildpneumonitis severe lifethreatening and fatal pulmonary adverse reactions consistent with interstitial lung disease ildpneumonitis have occurred with alunbrig in trial alta alta ildpneumonitis occurred in  of patients in the  mg group  mg once daily and  of patients in the → mg group  mg once daily with day leadin at  mg once daily adverse reactions consistent with possible ildpneumonitis occurred early within  days of initiation of alunbrig median onset was  days in  of patients with grade  to  reactions occurring in  monitor for new or worsening respiratory symptoms eg dyspnea cough etc particularly during the first week of initiating alunbrig withhold alunbrig in any patient with new or worsening respiratory symptoms and promptly evaluate for ildpneumonitis or other causes of respiratory symptoms eg pulmonary embolism tumor progression and infectious pneumonia for grade  or  ildpneumonitis either resume alunbrig with dose reduction after recovery to baseline or permanently discontinue alunbrig permanently discontinue alunbrig for grade  or  ildpneumonitis or recurrence of grade  or  ildpneumonitis hypertension in alta hypertension was reported in  of patients in the  mg group who received alunbrig and  of patients in the → mg group grade  hypertension occurred in  of patients overall control blood pressure prior to treatment with alunbrig monitor blood pressure after  weeks and at least monthly thereafter during treatment with alunbrig withhold alunbrig for grade  hypertension despite optimal antihypertensive therapy upon resolution or improvement to grade  severity resume alunbrig at a reduced dose consider permanent discontinuation of treatment with alunbrig for grade  hypertension or recurrence of grade  hypertension use caution when administering alunbrig in combination with antihypertensive agents that cause bradycardia bradycardia bradycardia can occur with alunbrig in alta heart rates less than  beats per minute bpm occurred in  of patients in the  mg group and  of patients in the → mg group grade  bradycardia occurred in   patient in the  mg group monitor heart rate and blood pressure during treatment with alunbrig monitor patients more frequently if concomitant use of drug known to cause bradycardia cannot be avoided for symptomatic bradycardia withhold alunbrig and review concomitant medications for those known to cause bradycardia if a concomitant medication known to cause bradycardia is identified and discontinued or dose adjusted resume alunbrig at the same dose following resolution of symptomatic bradycardia otherwise reduce the dose of alunbrig following resolution of symptomatic bradycardia discontinue alunbrig for lifethreatening bradycardia if no contributing concomitant medication is identified visual disturbance in alta adverse reactions leading to visual disturbance including blurred vision diplopia and reduced visual acuity were reported in  of patients treated with alunbrig in the  mg group and  of patients in the → mg group grade  macular edema and cataract occurred in one patient each in the → mg group advise patients to report any visual symptoms withhold alunbrig and obtain an ophthalmologic evaluation in patients with new or worsening visual symptoms of grade  or greater severity upon recovery of grade  or grade  visual disturbances to grade  severity or baseline resume alunbrig at a reduced dose permanently discontinue treatment with alunbrig for grade  visual disturbances creatine phosphokinase cpk elevation in alta creatine phosphokinase cpk elevation occurred in  of patients receiving alunbrig in the  mg group and  of patients in the  mg→ mg group the incidence of grade  cpk elevation was  in the  mg group and  in the → mg group dose reduction for cpk elevation occurred in  of patients in the  mg group and  in the → mg group advise patients to report any unexplained muscle pain tenderness or weakness monitor cpk levels during alunbrig treatment withhold alunbrig for grade  or  cpk elevation upon resolution or recovery to grade  or baseline resume alunbrig at the same dose or at a reduced dose pancreatic enzyme elevation in alta amylase elevation occurred in  of patients in the  mg group and  of patients in the → mg group lipase elevations occurred in  of patients in the  mg group and  of patients in the → mg group grade  or  amylase elevation occurred in  of patients in the  mg group and  of patients in the → mg group grade  or  lipase elevation occurred in  of patients in the  mg group and  of patients in the → mg group monitor lipase and amylase during treatment with alunbrig withhold alunbrig for grade  or  pancreatic enzyme elevation upon resolution or recovery to grade  or baseline resume alunbrig at the same dose or at a reduced dose hyperglycemia in alta  of patients who received alunbrig experienced new or worsening hyperglycemia grade  hyperglycemia based on laboratory assessment of serum fasting glucose levels occurred in  of patients two of   patients with diabetes or glucose intolerance at baseline required initiation of insulin while receiving alunbrig assess fasting serum glucose prior to initiation of alunbrig and monitor periodically thereafter initiate or optimize antihyperglycemic medications as needed if adequate hyperglycemic control cannot be achieved with optimal medical management withhold alunbrig until adequate hyperglycemic control is achieved and consider reducing the dose of alunbrig or permanently discontinuing alunbrig embryofetal toxicity based on its mechanism of action and findings in animals alunbrig can cause fetal harm when administered to pregnant women there are no clinical data on the use of alunbrig in pregnant women advise pregnant women of the potential risk to a fetus advise females of reproductive potential to use effective nonhormonal contraception during treatment with alunbrig and for at least  months following the final dose advise males with female partners of reproductive potential to use effective contraception during treatment and for at least  months after the last dose of alunbrig adverse reactions serious adverse reactions occurred in  of patients in the  mg group and  of patients in the → mg group the most common serious adverse reactions were pneumonia  overall  in the  mg group and  in the → mg group and ildpneumonitis  overall  in the  mg group and  in the → mg group fatal adverse reactions occurred in  of patients and consisted of pneumonia  patients sudden death dyspnea respiratory failure pulmonary embolism bacterial meningitis and urosepsis  patient each the most common adverse reactions ≥ in the  mg group were nausea  fatigue  headache  and dyspnea  and in the → mg group were nausea  diarrhea  fatigue  cough  and headache  drug interactions cypa inhibitors avoid concomitant use of alunbrig with strong cypa inhibitors avoid grapefruit or grapefruit juice as it may also increase plasma concentrations of brigatinib if concomitant use of a strong cypa inhibitor is unavoidable reduce the dose of alunbrig cypa inducers avoid concomitant use of alunbrig with strong cypa inducers cypa substrates coadministration of alunbrig with cypa substrates including hormonal contraceptives can result in decreased concentrations and loss of efficacy of cypa substrates use in specific populations pregnancy alunbrig can cause fetal harm advise females of reproductive potential of the potential risk to a fetus lactation advise lactating women not to breastfeed during treatment with alunbrig and for  week following the final dose females and males of reproductive potential contraception advise females of reproductive potential to use effective nonhormonal contraception during treatment with alunbrig and for at least  months after the final dose advise males with female partners of reproductive potential to use effective contraception during treatment with alunbrig and for at least  months after the final dose infertility alunbrig may cause reduced fertility in males pediatric use the safety and efficacy of alunbrig in pediatric patients have not been established geriatric use clinical studies of alunbrig did not include sufficient numbers of patients aged  years and older to determine whether they respond differently from younger patients of the  patients in alta  were  years and  were  years or older no clinically relevant differences in safety or efficacy were observed between patients ≥ and younger patients hepatic or renal impairment no dose adjustment is recommended for patients with mild hepatic impairment or mild or moderate renal impairment the safety of alunbrig in patients with moderate or severe hepatic impairment or severe renal impairment has not been studied you may report side effects to the fda at fda or wwwfdagovmedwatch you may also report side effects directly to takeda oncology at apoint  or medinfoariadcom please read full prescribing information for alunbrig   you are now leaving alunbrigcom the official site for alunbrig™ brigatinib this link will take you to the corporate takeda oncology website continue cancel you are now leaving alunbrigcom the official site for alunbrig™ brigatinib this link will take you to the alunbrig point™ website continue cancel you are now leaving alunbrigcom the official site for alunbrig™ brigatinib this link will take you to the fda website continue cancel the site you are about to enter is intended for us healthcare professionals only please confirm that you are a us healthcare professional yes i confirm that i am a us healthcare professional cancel ariad home page contact about ariadoverviewcontact infowwwtakedaoncologycomour name  logoour destinationour vision  cultural dnaleadership teampressroompress releasesabout ariadpharm on twittergrants  donationsphoto galleryvideo galleryemployee videosscience and research videosour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery alunbrig™ brigatinib now approved go ariad is now part of takeda pharmaceuticals click here to visit takedaoncologycom ‹ › alunbrig™ brigatinib now approved ariad is now part of takeda pharmaceuticals alunbrig™ brigatinib our second approved medicine an ariaddeveloped medicine click here for full us prescribing informationlearn more a remarkable place doing remarkable work were looking for people who want to make a difference for cancer patients open positions a unique highly targeted approach to cancer our research  development program learn more news  features latest news  takeda announces fda accelerated approval of alunbrig™ brigatinib read more  takeda completes acquisition of ariad pharmaceuticals inc read more ×  new video  ariad company video newariad company video click here to watch twitter feed ariadpharmaceuticals ariadpharmariad pharmaceuticals is now part of takedaoncology follow here for more information httpstconmiwmudklf httpstcojlddb months agoariadpharmaceuticals ariadpharmbreakingnews takedaoncology completes acquisition of ariad pharmaceuticals read the announcement… httpstcoyvtjelhadw months ago print page share page our photo gallery follow us about ariadoverviewcontact infoour name  logoour destinationour vision  cultural dnaleadership teampressroomgrants  donationsphoto galleryvideo galleryour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery   product information provided on this site is intended only for us residents  ariad pharmaceuticals inc all rights reserved terms and conditions privacy policy map  directions ariad pharmaceuticals  office in cambridge foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingplanning a trip to bostonfoursquare can help you find the best places to go tofind great things to doariad pharmaceuticalsofficecambridgesavesharetips photos ariad pharmaceuticals tip and reviewlog in to leave a tip herepostkristine nardelliapril  been here  timessola flour bytes thailand cafe and miracle of science are great places to eat lunch photorelated searchesariad pharmaceuticals cambridge  ariad pharmaceuticals cambridge photos  ariad pharmaceuticals cambridge location  ariad pharmaceuticals cambridge address  ariad pharmaceuticals cambridge  ariad pharmaceuticals cambridge  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeyfoursquare    lovingly made in nyc  sfariad pharmaceuticals landsdowne stcambridge ma united statesget directions none listed see when people check inpeople tend to check in during these timestoday am– pm pm– pmwed am– pmthu–fri am– pmsat–sunnonemon am– pmsee moreis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around you ariad home page contact about ariadoverviewcontact infowwwtakedaoncologycomour name  logoour destinationour vision  cultural dnaleadership teampressroompress releasesabout ariadpharm on twittergrants  donationsphoto galleryvideo galleryemployee videosscience and research videosour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery alunbrig™ brigatinib now approved go ariad is now part of takeda pharmaceuticals click here to visit takedaoncologycom ‹ › alunbrig™ brigatinib now approved ariad is now part of takeda pharmaceuticals alunbrig™ brigatinib our second approved medicine an ariaddeveloped medicine click here for full us prescribing informationlearn more a remarkable place doing remarkable work were looking for people who want to make a difference for cancer patients open positions a unique highly targeted approach to cancer our research  development program learn more news  features latest news  takeda announces fda accelerated approval of alunbrig™ brigatinib read more  takeda completes acquisition of ariad pharmaceuticals inc read more ×  new video  ariad company video newariad company video click here to watch twitter feed ariadpharmaceuticals ariadpharmariad pharmaceuticals is now part of takedaoncology follow here for more information httpstconmiwmudklf httpstcojlddb months agoariadpharmaceuticals ariadpharmbreakingnews takedaoncology completes acquisition of ariad pharmaceuticals read the announcement… httpstcoyvtjelhadw months ago print page share page our photo gallery follow us about ariadoverviewcontact infoour name  logoour destinationour vision  cultural dnaleadership teampressroomgrants  donationsphoto galleryvideo galleryour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery   product information provided on this site is intended only for us residents  ariad pharmaceuticals inc all rights reserved terms and conditions privacy policy map  directions ariad home page contact about ariadoverviewcontact infowwwtakedaoncologycomour name  logoour destinationour vision  cultural dnaleadership teampressroompress releasesabout ariadpharm on twittergrants  donationsphoto galleryvideo galleryemployee videosscience and research videosour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery alunbrig™ brigatinib now approved go ariad is now part of takeda pharmaceuticals click here to visit takedaoncologycom ‹ › alunbrig™ brigatinib now approved ariad is now part of takeda pharmaceuticals alunbrig™ brigatinib our second approved medicine an ariaddeveloped medicine click here for full us prescribing informationlearn more a remarkable place doing remarkable work were looking for people who want to make a difference for cancer patients open positions a unique highly targeted approach to cancer our research  development program learn more news  features latest news  takeda announces fda accelerated approval of alunbrig™ brigatinib read more  takeda completes acquisition of ariad pharmaceuticals inc read more ×  new video  ariad company video newariad company video click here to watch twitter feed ariadpharmaceuticals ariadpharmariad pharmaceuticals is now part of takedaoncology follow here for more information httpstconmiwmudklf httpstcojlddb months agoariadpharmaceuticals ariadpharmbreakingnews takedaoncology completes acquisition of ariad pharmaceuticals read the announcement… httpstcoyvtjelhadw months ago print page share page our photo gallery follow us about ariadoverviewcontact infoour name  logoour destinationour vision  cultural dnaleadership teampressroomgrants  donationsphoto galleryvideo galleryour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery   product information provided on this site is intended only for us residents  ariad pharmaceuticals inc all rights reserved terms and conditions privacy policy map  directions about ariad contact about ariadoverviewcontact infowwwtakedaoncologycomour name  logoour destinationour vision  cultural dnaleadership teampressroompress releasesabout ariadpharm on twittergrants  donationsphoto galleryvideo galleryemployee videosscience and research videosour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery home  about ariad  overview about ariad to transform cancer care to transform lives about ariadoverviewcontact infoour name  logoour destinationour vision  cultural dnaleadership teampressroomgrants  donationsphoto galleryvideo gallery print page share page ariad is a biotechnology company focused exclusively passionately on cancer ariad pharmaceuticals inc headquartered in cambridge massachusetts is focused on discovering developing and commercializing precision therapies for patients with rare cancers ariad is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia lung cancer and other rare cancers ariad utilizes computational and structural approaches to design smallmolecule drugs that overcome resistance to existing cancer medicines our vision and cultural dna clarity and purpose for our journey together more company leadership the right mix of talent expertise and experience more photo gallery see some of our people working together more our location visit our office more back to top our photo gallery follow us about ariadoverviewcontact infoour name  logoour destinationour vision  cultural dnaleadership teampressroomgrants  donationsphoto galleryvideo galleryour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery   product information provided on this site is intended only for us residents  ariad pharmaceuticals inc all rights reserved terms and conditions privacy policy map  directions current opportunities contact about ariadoverviewcontact infowwwtakedaoncologycomour name  logoour destinationour vision  cultural dnaleadership teampressroompress releasesabout ariadpharm on twittergrants  donationsphoto galleryvideo galleryemployee videosscience and research videosour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery home  careers  current opportunities careers a great place to build your career careersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery print page share page back to top our photo gallery follow us about ariadoverviewcontact infoour name  logoour destinationour vision  cultural dnaleadership teampressroomgrants  donationsphoto galleryvideo galleryour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery   product information provided on this site is intended only for us residents  ariad pharmaceuticals inc all rights reserved terms and conditions privacy policy map  directions pipeline contact about ariadoverviewcontact infowwwtakedaoncologycomour name  logoour destinationour vision  cultural dnaleadership teampressroompress releasesabout ariadpharm on twittergrants  donationsphoto galleryvideo galleryemployee videosscience and research videosour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery home  research  development  pipeline our pipeline robust focused exciting in its potential research  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policy print page share page our pipeline centers on promising internally developed compounds each was discovered by our own people each targets proven pathways to disrupting cancer growth each has potential for important patient impact our pipeline ponatinib product cml ph all refractory phase preclinicalproof of conceptpivotalapproved product cml nd line phase preclinicalproof of conceptpivotalapproved product cml doseranging phase preclinicalproof of conceptpivotalapproved product ph all with chemo st nd line phase preclinicalproof of conceptpivotalapproved product aml flt phase preclinicalproof of conceptpivotalapproved product lung cancer fgfr ret phase preclinicalproof of conceptpivotalapproved brigatinib product nonsmall cell lung cancer alk  resistant phase preclinicalproof of conceptpivotalapproved product nonsmall cell lung cancer alk  st line phase preclinicalproof of conceptpivotalapproved ap product nonsmall cell lung cancer egfr exon  her exon  phase preclinicalproof of conceptpivotalapproved immunokinase program product genetically validated kinase target phase preclinicalproof of conceptpivotalapproved undisclosed programs product undisclosed programs phase preclinicalproof of conceptpivotalapproved  includes investigatorsponsored trials back to top our photo gallery follow us about ariadoverviewcontact infoour name  logoour destinationour vision  cultural dnaleadership teampressroomgrants  donationsphoto galleryvideo galleryour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery   product information provided on this site is intended only for us residents  ariad pharmaceuticals inc all rights reserved terms and conditions privacy policy map  directions ariad pharmaceuticals inc  overview contactabout ariadoverviewcontact informationour name  logoour destinationour visioncompany leadershippressroompress releasesabout ariadpharm on twittergrants  donationsphoto galleryour medicinesresearch  developmentoverviewpipelineour scienceponatinibcml and ph allamlgistexpanded access programother targetsbrigatinibclinical trialspotential against alkapclinical trialspublicationsinvestigatorsponsored trialsinvestorsoverview news releases sec filings careersoverviewour vision  cultural dnaemployee benefitscurrent opportunitieseeoephoto galleryvideo gallery employee videosscience and research videoshome  investors  overviewinvestors key to longterm value discipline execution and consistent communicationinvestorsoverview news releases sec filings print pageemail pageshare pagecorporate profile ariad pharmaceuticals inc headquartered in cambridge massachusetts is focused on discovering developing and commercializing precision therapies for patients with rare cancers ariad is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia lung cancer and other rare cancers on january   it was announced that ariad has entered into a definitive agreement to be acquired by takeda and the transaction closed in midfebruary  for additional information visit httpwwwariadcom or follow ariad on twitter ariadpharmfundamental change company notice and offer to purchasefundamental change notice and offer news releasestakeda announces fda accelerated approval of alunbrig™ brigatinibtakeda completes acquisition of ariad pharmaceuticals incariad announces submission of marketing authorization application for brigatinib to the european medicines agencymore »upcoming eventsthere are currently no events scheduledmore »recent eventsdatetitle  pm gmtariad pharmaceuticals inc at the jefferies  london healthcare conference  am etariad’s third quarter  financial resultsmore »back to topour photo galleryfollow usabout ariadoverviewcontact infoour name  logoour destinationour vision  cultural dnacompany leadershippressroomgrants  donationsphoto galleryvideo galleryiclusigregoverviewabout iclusigariad passreghealthcare professionalspatients  caregiversresearch  developmentoverviewpipelineour scienceponatinibbrigatinibapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto galleryproduct information provided on this site is intended only for us residents ariad pharmaceuticals inc all rights reservedterms and conditionsprivacy policyforward looking statementmap  directions careers contact about ariadoverviewcontact infowwwtakedaoncologycomour name  logoour destinationour vision  cultural dnaleadership teampressroompress releasesabout ariadpharm on twittergrants  donationsphoto galleryvideo galleryemployee videosscience and research videosour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery home  careers  overview careers were building something exciting join us careersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery print page share page as ariad employees we have a chance to make a profound difference in the lives of cancer patients who currently have few or no treatment options nothing is more important to ariad’s future success than attracting and developing the best and brightest in life sciences the people of ariad come from a wide variety of backgrounds united by a strong set of values and a growing sense of excitement and possibility we’re working together to realize our vision to transform the lives of cancer patients through breakthrough medicines employee recruitment send us your resume view opportunities at ariad our vision and cultural dna clarity and purpose for our journey together more company videos this is ariad click here for videos employee benefits our benefits package is designed to attract and retain bright talented people more back to top our photo gallery follow us about ariadoverviewcontact infoour name  logoour destinationour vision  cultural dnaleadership teampressroomgrants  donationsphoto galleryvideo galleryour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery   product information provided on this site is intended only for us residents  ariad pharmaceuticals inc all rights reserved terms and conditions privacy policy map  directions ariad pharmaceuticals inc  news releases contactabout ariadoverviewcontact informationour name  logoour destinationour visioncompany leadershippressroompress releasesabout ariadpharm on twittergrants  donationsphoto galleryour medicinesresearch  developmentoverviewpipelineour scienceponatinibcml and ph allamlgistexpanded access programother targetsbrigatinibclinical trialspotential against alkapclinical trialspublicationsinvestigatorsponsored trialsinvestorsoverview news releases sec filings careersoverviewour vision  cultural dnaemployee benefitscurrent opportunitieseeoephoto galleryvideo gallery employee videosscience and research videoshome  investors  news releasesinvestors key to longterm value discipline execution and consistent communicationinvestorsoverview news releases sec filings print pageemail pageshare pagenews releasesthe news releases listed below were believed to be accurate in all material respects at the time of original issuance please note that we do not intend and assume no obligation to update correct or otherwise modify any of these press releases for events that occur subsequent to the original release date we suggest you review the more recent press releases in order to receive the most current information made available by ariadkeyword search        datetitle takeda announces fda accelerated approval of alunbrig™ brigatinib− alunbrig approved for alk metastatic nonsmall cell lung cancer nsclc patients who have progressed on or are intolerant to crizotinib – cambridge mass and osaka japan – april   – takeda pharmaceutical company limited tse  today announced that alunbrig™ brigatinib has received accelerated approval from the us food and drug administration fda for the treatment of patients with anaplastic lymphoma kinasepositive alk metastatic nonsmall cell lung cancer nsclc takeda completes acquisition of ariad pharmaceuticals inc– significantly enhances takeda’s global oncology portfolio – – accretive to fy underlying core earnings – – reinforces takeda’s commitment to developing medicines for patients living with cancer – cambridge mass and osaka japan february   – takeda pharmaceutical company limited tse  “takeda” today announced the completion of its acquisition of ariad pharmaceuticals inc nasdaq aria “ariad” for  per share in cash “we are very pleased to have complet ariad announces submission of marketing authorization application for brigatinib to the european medicines agencycambridge massbusiness wirefeb   ariad pharmaceuticals inc nasdaq aria today announced the submission of a marketing authorization application maa for its investigational oral anaplastic lymphoma kinase alk inhibitor brigatinib to the european medicines agency ema ariad is seeking marketing approval in the european union of brigatinib in adult patients with anaplastic lymphoma kinase alk nonsmall cell lung cancer ariad enters into definitive agreement to be acquired by takeda for  billionariad stockholders to receive  per share in cash cambridge massbusiness wirejan   ariad pharmaceuticals nasdaqaria “ariad” today announced it has entered into a definitive agreement to be acquired by takeda pharmaceutical company limited tse  “takeda” under which takeda will acquire all of the outstanding shares in ariad for  per share in cash or a total enterprise value of approximately  billion  takeda to acquire ariad pharmaceuticals inc– significantly enhances takeda’s global oncology portfolio – – accretive to fy underlying core earnings – – reinforces takeda’s commitment to developing medicines for patients living with cancer – strategic highlights highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and reinforcing existing strength in hematology  ariad to present at the th annual jp morgan healthcare conferencecambridge massbusiness wirejan   ariad pharmaceuticals inc nasdaq aria a rare cancerfocused innovative biotechnology company today announced that it will present at the th annual jp morgan healthcare conference paris panayiotopoulos president and chief executive officer will provide an overview of the company’s business on monday january   at  pm pt the ariad presentation will be webca back to topour photo galleryfollow usabout ariadoverviewcontact infoour name  logoour destinationour vision  cultural dnacompany leadershippressroomgrants  donationsphoto galleryvideo galleryiclusigregoverviewabout iclusigariad passreghealthcare professionalspatients  caregiversresearch  developmentoverviewpipelineour scienceponatinibbrigatinibapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto galleryproduct information provided on this site is intended only for us residents ariad pharmaceuticals inc all rights reservedterms and conditionsprivacy policyforward looking statementmap  directions pipeline contact about ariadoverviewcontact infowwwtakedaoncologycomour name  logoour destinationour vision  cultural dnaleadership teampressroompress releasesabout ariadpharm on twittergrants  donationsphoto galleryvideo galleryemployee videosscience and research videosour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery home  research  development  pipeline our pipeline robust focused exciting in its potential research  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policy print page share page our pipeline centers on promising internally developed compounds each was discovered by our own people each targets proven pathways to disrupting cancer growth each has potential for important patient impact our pipeline ponatinib product cml ph all refractory phase preclinicalproof of conceptpivotalapproved product cml nd line phase preclinicalproof of conceptpivotalapproved product cml doseranging phase preclinicalproof of conceptpivotalapproved product ph all with chemo st nd line phase preclinicalproof of conceptpivotalapproved product aml flt phase preclinicalproof of conceptpivotalapproved product lung cancer fgfr ret phase preclinicalproof of conceptpivotalapproved brigatinib product nonsmall cell lung cancer alk  resistant phase preclinicalproof of conceptpivotalapproved product nonsmall cell lung cancer alk  st line phase preclinicalproof of conceptpivotalapproved ap product nonsmall cell lung cancer egfr exon  her exon  phase preclinicalproof of conceptpivotalapproved immunokinase program product genetically validated kinase target phase preclinicalproof of conceptpivotalapproved undisclosed programs product undisclosed programs phase preclinicalproof of conceptpivotalapproved  includes investigatorsponsored trials back to top our photo gallery follow us about ariadoverviewcontact infoour name  logoour destinationour vision  cultural dnaleadership teampressroomgrants  donationsphoto galleryvideo galleryour medicinesour approved medicinesresearch  developmentoverviewpipelineour scienceapclinical trialspublicationsinvestigatorsponsored trialsexpanded access policyinvestorsoverviewnews releasessec filingscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery   product information provided on this site is intended only for us residents  ariad pharmaceuticals inc all rights reserved terms and conditions privacy policy map  directions ariad pharmaceuticals  wikipedia ariad pharmaceuticals from wikipedia the free encyclopedia   redirected from ariad pharmaceuticals inc jump to navigation search ariad pharmaceuticals inc former type subsidiary traded as nasdaq aria industry pharmaceuticals biotechnology fate merged with takeda pharmaceuticals founded  defunct  headquarters cambridge ma united states key people harvey berger ceo alex denner chairman of the board harvey berger retired as of december  chairman  ceo timothy p clackson president of research and development and chief scientific officer products ridaforolimus under development ponatinib fda approved trade name iclusig brigatinib under development revenue usm fy  operating income usm fy  net income usm fy  total assets usm fy  number of employees   website wwwariadcom ariad pharmaceuticals inc was an american oncology company founded in  and headquartered in cambridge massachusetts on february th  takeda announced it had completed its acquisition of ariad on december   the fda approved ariad pharmaceuticals leukemia drug iclusig for patients with all forms of chronic myeloid leukemia cml or philadelphia chromosomepositive acute lymphoblastic leukemia ph all who are resistant or unable to tolerate other tyrosine kinase therapies on the market the drug was temporarily withdrawn from the market in november  because of the risk of lifethreatening blood clots and severe narrowing of blood vessels this suspension was partially lifted on december   with ponatinib being issued revised prescribing information a new black box warning and a risk evaluation and mitigation strategy in place to better evaluate the risks and benefits of using the drug ariad also has brigatinib a lung cancer drug which has completed its registration trial in alk fusion driven nonsmall cell lung cancer as of june  in january  takeda announced it would acquire ariad for  billion expanding the companys oncology and hematology divisions the acquisition was completed on february th   contents  company history  products  fdaapproved products  products under development  see also  references  external links company historyedit ariad is engaged in the discovery development and commercialization of medicines for cancer patients it offers iclusig ponatinib a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia cml and philadelphia chromosomepositive acute lymphoblastic leukemia in the united states and europe various investigatorsponsored trials are ongoing in several indications including first line and second line cml acute lymphoblastic leukemia bcrabl acute myeloid leukemia flt inhibitor nonsmall cell lung cancer ret fgfr advanced biliary cancer with fgfr fusions and other cancers with activating mutations involving the following genes fgfr fgfr fgfr fgfr ret and kit in addition its product pipeline consists of brigatinib an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising nonsmall cell lung cancer this drug reported results of its registration trial at asco june   with encouraging results ap an inhibitor of solid tumors with egfr and her activating mutation which began phase i testing in the second quarter of  and ridaforolimus an investigational mtor inhibitor for various types of cancers the company sells and markets iclusig through specialty pharmacies and specialty distributors in the united states it has collaboration and license agreement with medinol ltd and icon medical corp to develop and commercialize stents and other medical devices to deliver ridaforolimus on february   ariad pharmaceuticals announced the appointment of sarissa capitals alexander j denner phd to a twoyear term on the companys board of directors previously denner served as a senior managing director at carl icahns icahn capital and is currently ariads secondlargest shareholder on january   ariad announced that denner had become the chairman of the board replacing harvey berger shortly thereafter the company announced the termination of its shareholders rights plan the poison pill in july  the company announced it was due to receive up to  million through a royalty financing deal with pdl biopharma on future sales of ponatinib productsedit fdaapproved productsedit ponatinib iclusig products under developmentedit ridaforolimus formerly deforolimus partnered with merck brigatinib formerly ap see alsoedit companies portal merck bristolmyers squibb pfizer referencesedit  a b c aria annual income statement  ariad pharmaceuticals inc annual financials marketwatch retrieved    ariad reports first quarter  financial results and development progress reuters   abramowicz mark  november  ponatinib withdrawn a pharmaceutical tragedy   drug safety and availability  fda drug safety communication fda asks manufacturer of the leukemia drug iclusig ponatinib to suspend marketing and sales center for drug evaluation and research   httpwwwgenengnewscomgennewshighlightstakedatoacquireariadpharmaceuticalsforb  search of ponatinib  list results clinicaltrialsgov better source needed  dongwan kim et al june  brigatinib in patients with crizotinibrefractory alk non–small cell lung cancer first report of efficacy and safety from a pivotal randomized phase  trial alta the american society of clinical oncology asco annual meeting cs maint explicit use of et al link  ap is ariads most recent internallydiscovered drug candidate ariad pharmaceuticals   ariad announces election of alex denner as chairman of the board of directors business wire   ariad announces termination of shareholder rights plan  business wire   ariad to receive upto m in royalty deal  gen genetic engineering  biotechnology news  biotech from bench to business  gen  external linksedit official ariad site v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitleariadpharmaceuticalsoldid categories companies listed on nasdaqmerckdefunct pharmaceutical companies of the united statespharmaceutical companies established in companies based in cambridge massachusettsbiotechnology companies of the united statescompanies in the nasdaq biotechnology index establishments in massachusettslife sciences industrybiotechnology companies established in hidden categories all articles lacking reliable referencesarticles lacking reliable references from october cs maint explicit use of et alpages using deprecated image syntaxpages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view ariad pharmaceuticals  wikipedia ariad pharmaceuticals from wikipedia the free encyclopedia   redirected from ariad pharmaceuticals inc jump to navigation search ariad pharmaceuticals inc former type subsidiary traded as nasdaq aria industry pharmaceuticals biotechnology fate merged with takeda pharmaceuticals founded  defunct  headquarters cambridge ma united states key people harvey berger ceo alex denner chairman of the board harvey berger retired as of december  chairman  ceo timothy p clackson president of research and development and chief scientific officer products ridaforolimus under development ponatinib fda approved trade name iclusig brigatinib under development revenue usm fy  operating income usm fy  net income usm fy  total assets usm fy  number of employees   website wwwariadcom ariad pharmaceuticals inc was an american oncology company founded in  and headquartered in cambridge massachusetts on february th  takeda announced it had completed its acquisition of ariad on december   the fda approved ariad pharmaceuticals leukemia drug iclusig for patients with all forms of chronic myeloid leukemia cml or philadelphia chromosomepositive acute lymphoblastic leukemia ph all who are resistant or unable to tolerate other tyrosine kinase therapies on the market the drug was temporarily withdrawn from the market in november  because of the risk of lifethreatening blood clots and severe narrowing of blood vessels this suspension was partially lifted on december   with ponatinib being issued revised prescribing information a new black box warning and a risk evaluation and mitigation strategy in place to better evaluate the risks and benefits of using the drug ariad also has brigatinib a lung cancer drug which has completed its registration trial in alk fusion driven nonsmall cell lung cancer as of june  in january  takeda announced it would acquire ariad for  billion expanding the companys oncology and hematology divisions the acquisition was completed on february th   contents  company history  products  fdaapproved products  products under development  see also  references  external links company historyedit ariad is engaged in the discovery development and commercialization of medicines for cancer patients it offers iclusig ponatinib a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia cml and philadelphia chromosomepositive acute lymphoblastic leukemia in the united states and europe various investigatorsponsored trials are ongoing in several indications including first line and second line cml acute lymphoblastic leukemia bcrabl acute myeloid leukemia flt inhibitor nonsmall cell lung cancer ret fgfr advanced biliary cancer with fgfr fusions and other cancers with activating mutations involving the following genes fgfr fgfr fgfr fgfr ret and kit in addition its product pipeline consists of brigatinib an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising nonsmall cell lung cancer this drug reported results of its registration trial at asco june   with encouraging results ap an inhibitor of solid tumors with egfr and her activating mutation which began phase i testing in the second quarter of  and ridaforolimus an investigational mtor inhibitor for various types of cancers the company sells and markets iclusig through specialty pharmacies and specialty distributors in the united states it has collaboration and license agreement with medinol ltd and icon medical corp to develop and commercialize stents and other medical devices to deliver ridaforolimus on february   ariad pharmaceuticals announced the appointment of sarissa capitals alexander j denner phd to a twoyear term on the companys board of directors previously denner served as a senior managing director at carl icahns icahn capital and is currently ariads secondlargest shareholder on january   ariad announced that denner had become the chairman of the board replacing harvey berger shortly thereafter the company announced the termination of its shareholders rights plan the poison pill in july  the company announced it was due to receive up to  million through a royalty financing deal with pdl biopharma on future sales of ponatinib productsedit fdaapproved productsedit ponatinib iclusig products under developmentedit ridaforolimus formerly deforolimus partnered with merck brigatinib formerly ap see alsoedit companies portal merck bristolmyers squibb pfizer referencesedit  a b c aria annual income statement  ariad pharmaceuticals inc annual financials marketwatch retrieved    ariad reports first quarter  financial results and development progress reuters   abramowicz mark  november  ponatinib withdrawn a pharmaceutical tragedy   drug safety and availability  fda drug safety communication fda asks manufacturer of the leukemia drug iclusig ponatinib to suspend marketing and sales center for drug evaluation and research   httpwwwgenengnewscomgennewshighlightstakedatoacquireariadpharmaceuticalsforb  search of ponatinib  list results clinicaltrialsgov better source needed  dongwan kim et al june  brigatinib in patients with crizotinibrefractory alk non–small cell lung cancer first report of efficacy and safety from a pivotal randomized phase  trial alta the american society of clinical oncology asco annual meeting cs maint explicit use of et al link  ap is ariads most recent internallydiscovered drug candidate ariad pharmaceuticals   ariad announces election of alex denner as chairman of the board of directors business wire   ariad announces termination of shareholder rights plan  business wire   ariad to receive upto m in royalty deal  gen genetic engineering  biotechnology news  biotech from bench to business  gen  external linksedit official ariad site v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitleariadpharmaceuticalsoldid categories companies listed on nasdaqmerckdefunct pharmaceutical companies of the united statespharmaceutical companies established in companies based in cambridge massachusettsbiotechnology companies of the united statescompanies in the nasdaq biotechnology index establishments in massachusettslife sciences industrybiotechnology companies established in hidden categories all articles lacking reliable referencesarticles lacking reliable references from october cs maint explicit use of et alpages using deprecated image syntaxpages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view ariad pharmaceuticals  wikipedia ariad pharmaceuticals from wikipedia the free encyclopedia   redirected from ariad pharmaceuticals inc jump to navigation search ariad pharmaceuticals inc former type subsidiary traded as nasdaq aria industry pharmaceuticals biotechnology fate merged with takeda pharmaceuticals founded  defunct  headquarters cambridge ma united states key people harvey berger ceo alex denner chairman of the board harvey berger retired as of december  chairman  ceo timothy p clackson president of research and development and chief scientific officer products ridaforolimus under development ponatinib fda approved trade name iclusig brigatinib under development revenue usm fy  operating income usm fy  net income usm fy  total assets usm fy  number of employees   website wwwariadcom ariad pharmaceuticals inc was an american oncology company founded in  and headquartered in cambridge massachusetts on february th  takeda announced it had completed its acquisition of ariad on december   the fda approved ariad pharmaceuticals leukemia drug iclusig for patients with all forms of chronic myeloid leukemia cml or philadelphia chromosomepositive acute lymphoblastic leukemia ph all who are resistant or unable to tolerate other tyrosine kinase therapies on the market the drug was temporarily withdrawn from the market in november  because of the risk of lifethreatening blood clots and severe narrowing of blood vessels this suspension was partially lifted on december   with ponatinib being issued revised prescribing information a new black box warning and a risk evaluation and mitigation strategy in place to better evaluate the risks and benefits of using the drug ariad also has brigatinib a lung cancer drug which has completed its registration trial in alk fusion driven nonsmall cell lung cancer as of june  in january  takeda announced it would acquire ariad for  billion expanding the companys oncology and hematology divisions the acquisition was completed on february th   contents  company history  products  fdaapproved products  products under development  see also  references  external links company historyedit ariad is engaged in the discovery development and commercialization of medicines for cancer patients it offers iclusig ponatinib a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia cml and philadelphia chromosomepositive acute lymphoblastic leukemia in the united states and europe various investigatorsponsored trials are ongoing in several indications including first line and second line cml acute lymphoblastic leukemia bcrabl acute myeloid leukemia flt inhibitor nonsmall cell lung cancer ret fgfr advanced biliary cancer with fgfr fusions and other cancers with activating mutations involving the following genes fgfr fgfr fgfr fgfr ret and kit in addition its product pipeline consists of brigatinib an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising nonsmall cell lung cancer this drug reported results of its registration trial at asco june   with encouraging results ap an inhibitor of solid tumors with egfr and her activating mutation which began phase i testing in the second quarter of  and ridaforolimus an investigational mtor inhibitor for various types of cancers the company sells and markets iclusig through specialty pharmacies and specialty distributors in the united states it has collaboration and license agreement with medinol ltd and icon medical corp to develop and commercialize stents and other medical devices to deliver ridaforolimus on february   ariad pharmaceuticals announced the appointment of sarissa capitals alexander j denner phd to a twoyear term on the companys board of directors previously denner served as a senior managing director at carl icahns icahn capital and is currently ariads secondlargest shareholder on january   ariad announced that denner had become the chairman of the board replacing harvey berger shortly thereafter the company announced the termination of its shareholders rights plan the poison pill in july  the company announced it was due to receive up to  million through a royalty financing deal with pdl biopharma on future sales of ponatinib productsedit fdaapproved productsedit ponatinib iclusig products under developmentedit ridaforolimus formerly deforolimus partnered with merck brigatinib formerly ap see alsoedit companies portal merck bristolmyers squibb pfizer referencesedit  a b c aria annual income statement  ariad pharmaceuticals inc annual financials marketwatch retrieved    ariad reports first quarter  financial results and development progress reuters   abramowicz mark  november  ponatinib withdrawn a pharmaceutical tragedy   drug safety and availability  fda drug safety communication fda asks manufacturer of the leukemia drug iclusig ponatinib to suspend marketing and sales center for drug evaluation and research   httpwwwgenengnewscomgennewshighlightstakedatoacquireariadpharmaceuticalsforb  search of ponatinib  list results clinicaltrialsgov better source needed  dongwan kim et al june  brigatinib in patients with crizotinibrefractory alk non–small cell lung cancer first report of efficacy and safety from a pivotal randomized phase  trial alta the american society of clinical oncology asco annual meeting cs maint explicit use of et al link  ap is ariads most recent internallydiscovered drug candidate ariad pharmaceuticals   ariad announces election of alex denner as chairman of the board of directors business wire   ariad announces termination of shareholder rights plan  business wire   ariad to receive upto m in royalty deal  gen genetic engineering  biotechnology news  biotech from bench to business  gen  external linksedit official ariad site v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitleariadpharmaceuticalsoldid categories companies listed on nasdaqmerckdefunct pharmaceutical companies of the united statespharmaceutical companies established in companies based in cambridge massachusettsbiotechnology companies of the united statescompanies in the nasdaq biotechnology index establishments in massachusettslife sciences industrybiotechnology companies established in hidden categories all articles lacking reliable referencesarticles lacking reliable references from october cs maint explicit use of et alpages using deprecated image syntaxpages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view ariad pharmaceuticals inc  product pipeline review   trends statistics segment and forecasts market size share analysis  market research store     gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals ariad pharmaceuticals inc  product pipeline review   published may  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample ariad pharmaceuticals inc  product pipeline review   summary global markets direct’s ‘ariad pharmaceuticals inc  product pipeline review  ’ provides an overview of the ariad pharmaceuticals inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of ariad pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of ariad pharmaceuticals inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of ariad pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the ariad pharmaceuticals inc’s pipeline products reasons to buy  evaluate ariad pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of ariad pharmaceuticals inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the ariad pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of ariad pharmaceuticals inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of ariad pharmaceuticals inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of ariad pharmaceuticals inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  ariad pharmaceuticals inc snapshot  ariad pharmaceuticals inc overview  key information  key facts  ariad pharmaceuticals inc  research and development overview  key therapeutic areas  ariad pharmaceuticals inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  combination treatment modalities  pipeline products  outlicensed products  outlicensed productscombination treatment modalities  ariad pharmaceuticals inc  pipeline products glance  ariad pharmaceuticals inc  clinical stage pipeline products  phase ii productscombination treatment modalities  ariad pharmaceuticals inc  early stage pipeline products  preclinical productscombination treatment modalities  ariad pharmaceuticals inc  drug profiles  brigatinib  product description  mechanism of action  rd progress  ponatinib hydrochloride  product description  mechanism of action  rd progress  ponatinib hydrochloride  ridaforolimus  product description  mechanism of action  rd progress  ap  product description  mechanism of action  rd progress  ariad pharmaceuticals inc  pipeline analysis  ariad pharmaceuticals inc  pipeline products by target  ariad pharmaceuticals inc  pipeline products by route of administration  ariad pharmaceuticals inc  pipeline products by molecule type  ariad pharmaceuticals inc  pipeline products by mechanism of action  ariad pharmaceuticals inc  recent pipeline updates  ariad pharmaceuticals inc  dormant projects  ariad pharmaceuticals inc  discontinued pipeline products  discontinued pipeline product profiles  ap  ponatinib hydrochloride  ariad pharmaceuticals inc  company statement  ariad pharmaceuticals inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables ariad pharmaceuticals inc key information  ariad pharmaceuticals inc key facts  ariad pharmaceuticals inc  pipeline by indication   ariad pharmaceuticals inc  pipeline by stage of development   ariad pharmaceuticals inc  monotherapy products in pipeline   ariad pharmaceuticals inc  combination treatment modalities in pipeline   ariad pharmaceuticals inc  outlicensed products in pipeline   ariad pharmaceuticals inc  outlicensed products combination treatment modalities   ariad pharmaceuticals inc  phase ii   ariad pharmaceuticals inc  preclinical   ariad pharmaceuticals inc  pipeline by target   ariad pharmaceuticals inc  pipeline by route of administration   ariad pharmaceuticals inc  pipeline by molecule type   ariad pharmaceuticals inc  pipeline products by mechanism of action   ariad pharmaceuticals inc  recent pipeline updates   ariad pharmaceuticals inc  dormant developmental projects  ariad pharmaceuticals inc  discontinued pipeline products   ariad pharmaceuticals inc subsidiaries  list of figures ariad pharmaceuticals inc  pipeline by top  indication   ariad pharmaceuticals inc  pipeline by stage of development   ariad pharmaceuticals inc  monotherapy products in pipeline   ariad pharmaceuticals inc  pipeline by top  target   ariad pharmaceuticals inc  pipeline by top  route of administration   ariad pharmaceuticals inc  pipeline by top  molecule type   ariad pharmaceuticals inc  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports global and china laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the global and china laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enh read more united states laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the united states laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enhanc read more europe laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the europe laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enhances the read more china laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the china laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enhances the u read more global laboratory ventilators market professional survey report forecast  mar  sp consulting  pages    code  mrs   this report studies laboratory ventilators in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  this report focuses on top manufacturers in global market with production price revenue and market share for each manufacturer covering harvard apparatus parr instrument harvard bioscience columbus instruments company  company   b read more global laboratory ventilators sales market report forecast  mar  sp consulting  pages    code  mrs   the report offers a comprehensive evaluation of the market it does so via indepth insights understanding market evolution by tracking historical developments and analyzing the present scenario and future projections based on optimistic and likely scenarios each research report serves as a repository of analysis and information for every facet of the market including but not limited to regional markets technology developments types applications and the competitive landscape the read more global laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the global laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enhances the read more global and china medical bone densitometers market research report forecast  mar  sp consulting  pages    code  mrs   the global and china medical bone densitometers market research report forecast  is a valuable source of insightful data for business strategists it provides the medical bone densitometers industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this medical bone densitometers market study provides comprehensive da read more united states medical bone densitometers market research report forecast  mar  sp consulting  pages    code  mrs   the united states medical bone densitometers market research report forecast  is a valuable source of insightful data for business strategists it provides the medical bone densitometers industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this medical bone densitometers market study provides comprehensive data read more europe medical bone densitometers market research report forecast  mar  sp consulting  pages    code  mrs   the europe medical bone densitometers market research report forecast  is a valuable source of insightful data for business strategists it provides the medical bone densitometers industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this medical bone densitometers market study provides comprehensive data which e read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports ariad pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports ariad pharmaceuticals inc  product pipeline review   ariad pharmaceuticals inc  product pipeline review   wgr  november  global  pages global markets direct description table of content sample report enquiry before buy related reports ariad pharmaceuticals inc  product pipeline review  summaryglobal markets direct’s ‘ariad pharmaceuticals inc  product pipeline review  ’ provides an overview of the ariad pharmaceuticals inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of ariad pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of ariad pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of ariad pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the ariad pharmaceuticals inc’s pipeline productsreasons to buy evaluate ariad pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of ariad pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the ariad pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of ariad pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of ariad pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of ariad pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures ariad pharmaceuticals inc snapshot ariad pharmaceuticals inc overview key information key facts ariad pharmaceuticals inc  research and development overview key therapeutic areas ariad pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  outlicensed products outlicensed productscombination treatment modalities ariad pharmaceuticals inc  pipeline products glance ariad pharmaceuticals inc  late stage pipeline products preregistration productscombination treatment modalities ariad pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities ariad pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities ariad pharmaceuticals inc  drug profiles ponatinib product description mechanism of action rd progress ap product description mechanism of action rd progress ponatinib  ridaforolimus product description mechanism of action rd progress ariad pharmaceuticals inc  pipeline analysis ariad pharmaceuticals inc  pipeline products by target ariad pharmaceuticals inc  pipeline products by route of administration ariad pharmaceuticals inc  pipeline products by molecule type ariad pharmaceuticals inc  pipeline products by mechanism of action ariad pharmaceuticals inc  recent pipeline updates ariad pharmaceuticals inc  dormant projects ariad pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles ap ponatinib ariad pharmaceuticals inc  company statement ariad pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesariad pharmaceuticals inc key information ariad pharmaceuticals inc key facts ariad pharmaceuticals inc  pipeline by indication  ariad pharmaceuticals inc  pipeline by stage of development  ariad pharmaceuticals inc  monotherapy products in pipeline  ariad pharmaceuticals inc  combination treatment modalities in pipeline  ariad pharmaceuticals inc  outlicensed products in pipeline  ariad pharmaceuticals inc  outlicensed products combination treatment modalities  ariad pharmaceuticals inc  preregistration  ariad pharmaceuticals inc  phase ii  ariad pharmaceuticals inc  preclinical  ariad pharmaceuticals inc  pipeline by target  ariad pharmaceuticals inc  pipeline by route of administration  ariad pharmaceuticals inc  pipeline by molecule type  ariad pharmaceuticals inc  pipeline products by mechanism of action  ariad pharmaceuticals inc  recent pipeline updates  ariad pharmaceuticals inc  dormant developmental projects ariad pharmaceuticals inc  discontinued pipeline products  ariad pharmaceuticals inc subsidiaries list of figuresariad pharmaceuticals inc  pipeline by top  indication  ariad pharmaceuticals inc  pipeline by stage of development  ariad pharmaceuticals inc  monotherapy products in pipeline  ariad pharmaceuticals inc  outlicensed products in pipeline  ariad pharmaceuticals inc  pipeline by top  target  ariad pharmaceuticals inc  pipeline by top  route of administration  ariad pharmaceuticals inc  pipeline by top  molecule type  ariad pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send ariad pharmaceuticals inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report ariad pharmaceuticals inc  product pipeline review   published by global markets direct product code  published may   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license ariad pharmaceuticals inc  product pipeline review   published may   content info  pages description summary global markets directs ariad pharmaceuticals inc  product pipeline review   provides an overview of the ariad pharmaceuticals incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of ariad pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of ariad pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of ariad pharmaceuticals incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the ariad pharmaceuticals incs pipeline products reasons to buy evaluate ariad pharmaceuticals incs strategic position with total access to detailed information on its product pipeline assess the growth potential of ariad pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the ariad pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of ariad pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of ariad pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of ariad pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdb table of contents table of contents list of tables list of figures ariad pharmaceuticals inc snapshot ariad pharmaceuticals inc overview key information key facts ariad pharmaceuticals inc  research and development overview key therapeutic areas ariad pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  outlicensed products outlicensed productscombination treatment modalities ariad pharmaceuticals inc  pipeline products glance ariad pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities ariad pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities ariad pharmaceuticals inc  drug profiles brigatinib product description mechanism of action rd progress ponatinib hydrochloride product description mechanism of action rd progress ponatinib hydrochloride  ridaforolimus product description mechanism of action rd progress ap product description mechanism of action rd progress ariad pharmaceuticals inc  pipeline analysis ariad pharmaceuticals inc  pipeline products by target ariad pharmaceuticals inc  pipeline products by route of administration ariad pharmaceuticals inc  pipeline products by molecule type ariad pharmaceuticals inc  pipeline products by mechanism of action ariad pharmaceuticals inc  recent pipeline updates ariad pharmaceuticals inc  dormant projects ariad pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles ap ponatinib hydrochloride ariad pharmaceuticals inc  company statement ariad pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables ariad pharmaceuticals inc key information ariad pharmaceuticals inc key facts ariad pharmaceuticals inc  pipeline by indication  ariad pharmaceuticals inc  pipeline by stage of development  ariad pharmaceuticals inc  monotherapy products in pipeline  ariad pharmaceuticals inc  combination treatment modalities in pipeline  ariad pharmaceuticals inc  outlicensed products in pipeline  ariad pharmaceuticals inc  outlicensed products combination treatment modalities  ariad pharmaceuticals inc  phase ii  ariad pharmaceuticals inc  preclinical  ariad pharmaceuticals inc  pipeline by target  ariad pharmaceuticals inc  pipeline by route of administration  ariad pharmaceuticals inc  pipeline by molecule type  ariad pharmaceuticals inc  pipeline products by mechanism of action  ariad pharmaceuticals inc  recent pipeline updates  ariad pharmaceuticals inc  dormant developmental projects ariad pharmaceuticals inc  discontinued pipeline products  ariad pharmaceuticals inc subsidiaries list of figures ariad pharmaceuticals inc  pipeline by top  indication  ariad pharmaceuticals inc  pipeline by stage of development  ariad pharmaceuticals inc  monotherapy products in pipeline  ariad pharmaceuticals inc  pipeline by top  target  ariad pharmaceuticals inc  pipeline by top  route of administration  ariad pharmaceuticals inc  pipeline by top  molecule type  ariad pharmaceuticals inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved takeda completes acquisition of ariad pharmaceuticals inc better health brighter future takeda completes acquisition of ariad pharmaceuticals inc  february  cambridge mass and osaka japan – significantly enhances takeda’s global oncology portfolio– accretive to fy underlying core earnings– reinforces takeda’s commitment to developing medicines for patients living with cancer takeda pharmaceutical company limited tse  “takeda” today announced the completion of its acquisition of ariad pharmaceuticals inc nasdaq aria “ariad” for  per share in cash “we are very pleased to have completed the acquisition of ariad pharmaceuticals the addition of ariad’s innovative targeted therapies and research and development capabilities strengthens and diversifies our oncology business positioning takeda for sustainable longterm growth in this priority therapeutic area” said christophe weber president and chief executive officer of takeda “we are particularly excited by the global potential of brigatinib an investigational drug product which we believe will become a bestinclass alk inhibitor for nonsmall cell lung cancer with the potential to achieve peak annual sales of over  billion we are also impressed with the swiftness and agility of takeda and ariad employees as they have planned for a successful integration while remaining focused on strategic goals this bodes very well for the future of our combined business and we look forward to building on this strong start to maximize the benefit of iclusig®ponatinib and potential of brigatinib for cancer patients” “the acquisition of ariad is transformational for takeda oncology iclusig enhances our strong position in hematology in the us and brigatinib has the potential to broaden our solid tumor franchise globally” said christophe bianchi president of takeda oncology “there is a strong cultural fit between our two companies with a shared mission to advance innovative therapies to improve the lives of patients with cancer we have been working together over the past month to plan for a smooth integration of our businesses and we will work closely with regulatory authorities on our brigatinib market authorization submissions” takeda continues to expect the transaction to be accretive to underlying core earnings by fy strong revenue growth and synergy savings will offset increased sales and marketing costs for the anticipated brigatinib launch tender offer details takeda completed the acquisition through a tender offer and subsequent merger of ariad with kiku merger co inc a wholly owned subsidiary of takeda pharmaceuticals usa ariad is now an indirect wholly owned subsidiary of takeda the tender offer for all of the outstanding shares of ariad common stock expired as scheduled immediately following the offer’s expiration time of  pm eastern time on february   computershare trust company na the depositary and paying agent for the tender offer has advised takeda that  shares of ariad common stock were tendered representing approximately  of the shares outstanding all of the conditions to the tender offer having been satisfied takeda’s indirect wholly owned subsidiary kiku merger co inc has accepted for payment and will promptly pay for all shares tendered the transaction will be funded by approximately  billion of new debt and the remainder from existing cash takeda is expected to remain investment grade and the transaction has no impact on takeda’s dividend policy on february   takeda completed its acquisition of ariad through the merger of kiku merger co inc with ariad without a vote of ariad’s shareholders pursuant to section h if the delaware general corporation law as a result of the merger ariad became an indirect wholly owned subsidiary of takeda in connection with the merger all ariad shares not purchased in the tender offer have been converted into the right to receive  per share in cash without interest less any required withholding taxes the same amount paid for all shares validly tendered and not validly withdrawn in the tender offer ariad common stock will cease to be traded on the nasdaq global select market evercore partners acted as financial advisor and cleary gottlieb steen  hamilton llp acted as legal advisor to takeda jp morgan securities llc goldman sachs  co and lazard acted as financial advisors and paul weiss rifkind wharton  garrison llp acted as legal advisor to ariad about takeda pharmaceutical company takeda pharmaceutical company limited is a global research and developmentdriven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into lifechanging medicines takeda focuses its rd efforts on oncology gastroenterology and central nervous system therapeutic areas plus vaccines takeda conducts rd both internally and with partners to stay at the leading edge of innovation new innovative products especially in oncology and gastroenterology as well as our presence in emerging markets fuel the growth of takeda more than  takeda employees are committed to improving quality of life for patients working with our partners in health care in more than  countries additional information about takeda is available through its corporate website wwwtakedacom please see iclusig® ponatinib full prescribing information including boxed warning media and investor contacts takeda investor contactnoriko higuchinorikohiguchitakedacom   takeda media outside japanshawn goodmanshawngoodmantakedacom japanese mediatsuyoshi tadatsuyoshitadatakedacom   kal goldberg finsburykalgoldbergfinsburycom chris ryall finsburychrisryallfinsburycom cautionary statement regarding forwardlooking statements this press release contains forwardlooking statements when used in this press release the words “can” “will” “believes” “intends” “expects” “is expected” similar expressions and any other statements that are not historical facts are intended to identify those assertions as forwardlooking statements such statements are based on a number of assumptions that could ultimately prove inaccurate and are subject to a number of risks neither takeda nor ariad assumes any obligation to update any forwardlooking statement whether as a result of new information future events or otherwise unless required by law copyright  takeda pharmaceutical company limited all rights reserved we use cookies to gather web statistics that help us improve our site we store no personal details accept read more ariad pharmaceuticals inc  product pipeline review    reportsnreports market research report welcome guest    registerlogin   contact us   about us      advanced search home ›  pharmaceuticals ›  report detail ariad pharmaceuticals inc  product pipeline review   published may  no of pages  price  single user license us   corporate user license us     report description table of contents inquire before buying global markets directs ariad pharmaceuticals inc  product pipeline review   provides an overview of the ariad pharmaceuticals incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of ariad pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of ariad pharmaceuticals inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of ariad pharmaceuticals incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the ariad pharmaceuticals incs pipeline productsreasons to buyevaluate ariad pharmaceuticals incs strategic position with total access to detailed information on its product pipelineassess the growth potential of ariad pharmaceuticals inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the ariad pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of ariad pharmaceuticals inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of ariad pharmaceuticals incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of ariad pharmaceuticals inc and identify potential opportunities in those areasavoid intellectual property rights related issues ariad pharmaceuticals inc  product pipeline review   table of contentstable of contents list of tables list of figures ariad pharmaceuticals inc snapshot ariad pharmaceuticals inc overview key information key facts ariad pharmaceuticals inc  research and development overview key therapeutic areas ariad pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  outlicensed products outlicensed productscombination treatment modalities ariad pharmaceuticals inc  pipeline products glance ariad pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities ariad pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities ariad pharmaceuticals inc  drug profiles brigatinib product description mechanism of action rd progress ponatinib hydrochloride product description mechanism of action rd progress ponatinib hydrochloride  ridaforolimus product description mechanism of action rd progress ap product description mechanism of action rd progress ariad pharmaceuticals inc  pipeline analysis ariad pharmaceuticals inc  pipeline products by target ariad pharmaceuticals inc  pipeline products by route of administration ariad pharmaceuticals inc  pipeline products by molecule type ariad pharmaceuticals inc  pipeline products by mechanism of action ariad pharmaceuticals inc  recent pipeline updates ariad pharmaceuticals inc  dormant projects ariad pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles ap ponatinib hydrochloride ariad pharmaceuticals inc  company statement ariad pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesariad pharmaceuticals inc key information ariad pharmaceuticals inc key facts ariad pharmaceuticals inc  pipeline by indication  ariad pharmaceuticals inc  pipeline by stage of development  ariad pharmaceuticals inc  monotherapy products in pipeline  ariad pharmaceuticals inc  combination treatment modalities in pipeline  ariad pharmaceuticals inc  outlicensed products in pipeline  ariad pharmaceuticals inc  outlicensed products combination treatment modalities  ariad pharmaceuticals inc  phase ii  ariad pharmaceuticals inc  preclinical  ariad pharmaceuticals inc  pipeline by target  ariad pharmaceuticals inc  pipeline by route of administration  ariad pharmaceuticals inc  pipeline by molecule type  ariad pharmaceuticals inc  pipeline products by mechanism of action  ariad pharmaceuticals inc  recent pipeline updates  ariad pharmaceuticals inc  dormant developmental projects ariad pharmaceuticals inc  discontinued pipeline products  ariad pharmaceuticals inc subsidiaries list of figuresariad pharmaceuticals inc  pipeline by top  indication  ariad pharmaceuticals inc  pipeline by stage of development  ariad pharmaceuticals inc  monotherapy products in pipeline  ariad pharmaceuticals inc  pipeline by top  target  ariad pharmaceuticals inc  pipeline by top  route of administration  ariad pharmaceuticals inc  pipeline by top  molecule type  ariad pharmaceuticals inc  pipeline products by top  mechanism of action   published by global markets direct product code global markets direct did you find what you arewere looking for  if not read below and browse through other relevant pages for similar market research reports or get in touch with us through the formcontact info in your right navigation panel and well share relevant market report titles for you to explore related reports global pharmaceutical plastic packaging market  by type by drug delivery by polymer type by packaging type by region by country opportunities and forecast  – by type rigid  packaging by packaging type plastic bottles blister pack caps  closures prefilled syringe others by drug delivery oral parenteral inhalation transdermal by polymer polypropylene pvc hdpe ldpe polyester polystyrene others executive summary a comprehensive research report created through extensive primary research inputs from industry experts companies stakeholders and secondary research the report aims to present the analysis of global pharmaceutical plastic pac global and europe bcg vaccine market  analysis and outlook to  this report presents a comprehensive overview of the bcg vaccine market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynamics stru global methadone market professional survey report  this report studies methadone in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  this r global nonwoven adhesive tape market professional survey report  this report studies nonwoven adhesive tape in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  global nonopioid pain patch market professional survey report  this report studies nonopioid pain patch in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  global culture media market professional survey report  this report studies culture media in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  th global herceptin biosimilar market professional survey report  this report studies herceptin biosimilar in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  global granulocytecolony stimulating factor market professional survey report  this report studies granulocytecolony stimulating factor in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and global glycosylated peptide market professional survey report  this report studies glycosylated peptide in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  global glycosylated hemoglobin cpeptide market professional survey report  this report studies glycosylated hemoglobin cpeptide in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and for why reportsnreportscom  market research reports and growing top fortune  organizations trust us for research data  support on call as well as emails your details are safe with us free support for your research requirements report delivery email delivery time upto  hrs  working days upto  hrs max  weekends and public holidays research support  custom research if this business study does not have the data and information analysis you need contact us with your research requirements we explore available market research reports to map your needs and share report titles with you alternatively we can also offer custom research that suits your budget and timelines share your information requirements here connect with us email salesreportsandreportscom call       home category publisher country latest reports markets discounted reports upcoming reports contact us subscription option using our subscription option you get access to market research reports and industry data of consumer goods market as per your needs get the best of consumer goods research reports by utilizing your research budgets in an optimum way more about our subscription option report alerts get email alerts about market research reports from industries and publishers of your interest please enter a valid email id thank you you have successfully subscribed to our report alerts avail upto  discount on below publisher reports technavio azoth analytics   reportsnreports all rights reserved disclamer privacy policy  terms and conditions  our market research blog  sitemap feeds rss  latest reports takeda to acquire ariad pharmaceuticals inc better health brighter future takeda to acquire ariad pharmaceuticals inc  january  cambridge mass and osaka japan – significantly enhances takeda’s global oncology portfolio– accretive to fy underlying core earnings– reinforces takeda’s commitment to developing medicines for patients living with cancer strategic highlights highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and reinforcing existing strength in hematology accretive to takeda’s underlying core earnings by fy and generates immediate and longterm revenue growth attractive value drivers include two very innovative precision medicines iclusig®ponatinib and brigatinib an exciting early stage pipeline and cost synergies iclusig is a globally commercialized product with continued strong sales growth potential brigatinib approval in the us is expected in the first half of  with peak sales potential over  billion and the potential to be the bestinclass alk inhibitor takeda will leverage ariad’s research and development capabilities and platform takeda retains financial flexibility with no impact on dividend policy takeda pharmaceutical company limited tse  “takeda” and ariad pharmaceuticals inc nasdaq aria “ariad” today announced that they have entered into a definitive agreement under which takeda will acquire all of the outstanding shares in ariad for  per share in cash or an enterprise value of approximately  billion the transaction has been approved unanimously by the boards of directors of both companies and is expected to close by the end of february  subject to required regulatory approvals and other customary closing conditions sarissa capital the holder of  of ariad’s common shares as well as each of the members of ariad’s board of directors have agreed to tender their shares to takeda pursuant to the offer “the acquisition of ariad is a unique opportunity that will enable us to positively impact the lives of more patients worldwide advance our strategic priorities and generate attractive returns for our shareholders” said christophe weber president and chief executive officer of takeda “this is a very exciting time for takeda as we will broaden our hematology portfolio and transform our global solid tumor franchise through the addition of two innovative targeted therapies opportunities to acquire such highquality complementary targeted therapies do not come often and we are very excited about the potential for this transaction to benefit patients our shareholders and other stakeholders” paris panayiotopoulos president and chief executive officer of ariad said “we are very pleased to combine with takeda which will allow us to not only accelerate our mission to discover develop and deliver precision therapies to patients with rare cancers but also deliver immediate and meaningful value to our shareholders through a substantial cash premium this exciting transaction is a testament to the hard work and dedication of ariad’s talented team of employees we have tremendous respect for takeda and i believe our shared commitment to innovation and researchdriven cultures will provide for a smooth transition” “this transaction is a great outcome for shareholders of ariad and takeda both ariad and takeda are passionate about helping cancer patients and i believe the talent and resources of takeda coupled with ariad’s pipeline and people will accelerate the development of cancer treatments i would like to extend my deepest gratitude to the management team and everyone at ariad for their unrelenting dedication” said alexander j denner phd chairman of the board of ariad highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and reinforcing existing strength in hematology the acquisition of ariad brings two innovative targeted therapies that will expand and enhance takeda’s existing oncology portfolio brigatinib an investigational drug product has the potential to add a differentiated global therapy in a geneticallydefined subpopulation of nonsmall cell lung cancer nsclc the addition of iclusig will broaden takeda’s strong hematology franchise to include chronic myeloid leukemia cml and a subset of acute lymphoblastic leukemia all together these two innovative targeted therapies will position takeda for sustainable longterm growth in oncology takeda’s track record of successful oncology product launches adcetris® brentuximab vedotin ninlarotm ixazomib and velcade® bortezomib means it has the experience and expertise required to deliver the successful launch of brigatinib and to ensure that it achieves global reach and share of voice thereafter accretive to takeda’s underlying core earnings by fy and generates immediate and longterm revenue growth the transaction is a compelling opportunity for takeda shareholders it will provide immediate revenue bring considerable longterm revenue potential and deliver synergy savings ariad provided calendar year  revenue guidance for iclusig of  million and takeda expects significant longterm revenue potential from the two lead assets takeda projects the acquisition of ariad to be accretive to underlying core earnings by fy and broadly neutral in fy strong revenue growth and synergy savings will offset increased sales and marketing costs for the brigatinib launch attractive value drivers include two very innovative medicines iclusig and brigatinib an exciting early stage pipeline and cost synergies iclusig a commercialized therapy with continued strong sales growth potential delivers immediate value brigatinib an investigational drug product with peak annual sales potential of over  billion will generate significant longterm value for takeda us approval is expected in the first half of  with global filing thereafter beyond iclusig and brigatinib ariad’s commitment and expertise in targeted kinase inhibition linked to strong translational science generated further pipeline opportunities which provide additional longterm upside potential takeda will leverage ariad’s rd capabilities and platform and largely absorb its rd costs within takedas existing rd budget ga cost synergies will be fully captured by fy takeda retains financial flexibility with no impact on dividend policy the transaction will be funded by up to  billion of new debt and the remainder from existing cash fy net debtebitda is estimated at approximately x which is expected to remain investment grade the transaction has no impact on takeda’s dividend policy transaction terms the acquisition is structured as an all cash tender offer by a subsidiary of takeda for all of the outstanding shares of ariad common stock followed by a merger in which remaining shares of ariad would be converted into the right to receive the same  cash per share price paid in the tender offer and ariad will become an indirect wholly owned subsidiary of takeda the transaction is subject to the tender of a majority of the outstanding shares of ariad common stock as well as other customary closing conditions including expiration of the applicable waiting period under the hartscottrodino antitrust improvements act of  and the antitrust laws of applicable foreign jurisdictions the transaction is expected to close by the end of february  takeda pharmaceuticals usa a wholly owned subsidiary of takeda has established kiku merger co inc to effect the transaction  tender offeror kiku merger co inc  target company ariad pharmaceuticals inc  class of shares to be acquired common stock  tender offer price  per share  acquisition amount aggregate tender offer price approximately  billion estimate  the amount is an estimated amount calculated by multiplying the number of the target companys shares fully diluted basis by the tender offer price per share it does not include advisory fees  payment cash  funded by up to  billion of new debt and the remainder from existing cash  period of tender offer from january  to february   the initial period of the tender offer will commence within  business days following execution of the merger agreement with ariad january   us and will close  business days after commencement if the situation arises whereby the conditions of the tender offer are not satisfied the period of the tender offer will be extended but the extension period will not exceed may  or august  if antitrust clearance not received  minimum number of shares to be purchased consummation of the tender offer will occur once the majority of shares outstanding of the company have been tendered and other customary closing conditions have been satisfied  financial advisor to takeda evercore partners  legal counsel to takeda cleary gottlieb steen  hamilton llp  financial advisor to ariad jp morgan securities llc goldman sachs  co lazard  legal counsel to ariad paul weiss rifkind wharton  garrison llp   overview of ariad  company name ariad pharmaceuticals inc  headquarters  binney street cambridge massachusetts  usa  representative paris panayiotopoulos president and chief executive officer  business description ariad pharmaceuticals inc headquartered in cambridge massachusetts is focused on discovering developing and commercializing precision therapies for patients with rare cancers ariad is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia lung cancer and other rare cancers ariad utilizes computational and structural approaches to design smallmolecule drugs that overcome resistance to existing cancer medicines  capital us million additional paidin capital as of december    date of establishment april   major shareholders and percentage of shares held wellington management group llp  fmr llc  vanguard group inc  others  relationships between takeda capital relationship not applicable personnel relationship not applicable transactional relationship not applicable  operating result and financial conditions for the last three years consolidated accounting period fiscal year ended december   fiscal year ended december   fiscal year ended december   net assets us in thousands    total assets us in thousands    net assets per share us    revenue us in thousands    operating profit us in thousands    net loss us in thousands    net loss per share us     as reported in the f filings percentage of shares is calculated by dividing the number of shareholdings as of the end of september  by the number of total shares outstanding of the target company   change in ownership before and after acquisition  number of shares already acquired  shares percentage of voting rights   number of shares to be acquired  shares percentage of voting rights  planned  total shares outstanding   schedule  board meeting resolution january    signing date january    commencement date and settlement date of the tender offer from january  to february  the initial period of the tender offer will commence within  business days following execution of the merger agreement with ariad january   us and will close  business days after commencement if the conditions of the tender offer are not satisfied the period of the tender offer will be extended but the extension period will not exceed may  or august  if antitrust clearance not received  completion of acquisition by the end of february  planned    fulfillment of the terms and conditions of the us antitrust law and the satisfaction of certain other customary conditions are required to complete the acquisition outlook fy at this stage we expect minimal impact on underlying revenue and underlying core earnings we do expect to incur transition and integration expenses however these expenses are not material to the current year result we will incorporate the financial impact in our fy consolidated earnings forecast and announce at the third quarter earnings conference in february  fy and beyond it is expected that the acquisition of ariad will be accretive to takeda’s underlying core earnings by fy and broadly neutral in fy strong revenue growth and synergy savings will offset increased sales and marketing costs for the brigatinib launch takeda’s financial guidance including eps for fy will be announced when takeda reports earnings for fy in may  conference call webcast information takeda will host a mediainvestors conference call at  pm est january    am jst january   to discuss the transaction you can listen to the conference call at the following linkhttpwwwtakedacominvestorinformationresults a replay of the conference call will be available within  hours in light of this announcement ariad will not be presenting today at the th annual jp morgan healthcare conference about takeda pharmaceutical company takeda pharmaceutical company limited is a global research and developmentdriven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into lifechanging medicines takeda focuses its rd efforts on oncology gastroenterology and central nervous system therapeutic areas plus vaccines takeda conducts rd both internally and with partners to stay at the leading edge of innovation new innovative products especially in oncology and gastroenterology as well as our presence in emerging markets fuel the growth of takeda more than  takeda employees are committed to improving quality of life for patients working with our partners in health care in more than  countries additional information about takeda is available through its corporate website httpbetterhealthtakedacom media and investor contacts takeda investor contactnoriko higuchinorikohiguchitakedacom   takeda media outside japanshawn goodmanshawngoodmantakedacom japanese mediatsuyoshi tadatsuyoshitadatakedacom   kal goldberg finsburykalgoldbergfinsburycom chris ryall finsburychrisryallfinsburycom ariad investor contactmanmeet sonimanmeetsoniariadcom ariad media contactssteve frankel jed repko leigh parrish joele frank wilkinson brimmer katcher    about iclusig® ponatinib tablets iclusig is a kinase inhibitor the primary target for iclusig is bcrabl an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia cml and philadelphiachromosome positive acute lymphoblastic leukemia ph all iclusig was designed using ariads computational and structurebased drugdesign platform specifically to inhibit the activity of bcrabl iclusig targets not only native bcrabl but also its isoforms that carry mutations that confer resistance to treatment including the ti mutation which has been associated with resistance to other approved tkis iclusig is approved in the us eu australia switzerland israel canada and japanin the us iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or philadelphia chromosome positive acute lymphoblastic leukemia ph all for whom no other tyrosine kinase inhibitor tki therapy is indicated treatment of adult patients with tipositive chronic myeloid leukemia chronic phase accelerated phase or blast phase or tipositive ph all limitations of uselimitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cmlimportant safety informationbased on the phase   mo followup analysis n except where notedimportant us safety information including the boxed warningwarning arterial occlusion venous thromboembolism heart failure and hepatotoxicity see full prescribing information for complete boxed warning arterial occlusion has occurred in at least  of iclusig® ponatinibtreated patients including fatal myocardial infarction stroke stenosis of large arterial vessels of the brain severe peripheral vascular disease and the need for urgent revascularization procedures patients with and without cardiovascular risk factors including patients less than  years old experienced these events interrupt or stop iclusig immediately for arterial occlusion a benefitrisk consideration should guide a decision to restart iclusig venous thromboembolism has occurred in  of iclusigtreated patients monitor for evidence of thromboembolism consider dose modification or discontinuation of iclusig in patients who develop serious venous thromboembolism heart failure including fatalities occurred in  of iclusig treated patients monitor cardiac function interrupt or stop iclusig for new or worsening heart failure hepatotoxicity liver failure and death have occurred in iclusigtreated patients monitor hepatic function interrupt iclusig if hepatotoxicity is suspected warnings and precautions arterial occlusions arterial occlusions including fatal myocardial infarction stroke stenosis of large arterial vessels of the brain severe peripheral vascular disease have occurred in at least  of iclusigtreated patients from the phase  and phase  trials in the phase  trial   of iclusigtreated patients experienced a cardiac vascular  peripheral vascular  or cerebrovascular  arterial occlusive event some patients experienced more than  type of event fatal and lifethreatening events have occurred within  weeks of starting treatment with doses as low as  mg per day iclusig can also cause recurrent or multisite vascular occlusion patients have required revascularization procedures the median time to onset of the first cardiac vascular cerebrovascular and peripheral vascular arterial occlusive events was   and  days respectively patients with and without cardiovascular risk factors some age  years or younger experienced these events the most common risk factors observed with these events were hypertension hyperlipidemia and history of cardiac disease arterial occlusive events were more frequent with increasing age and in patients with a history of ischemia hypertension diabetes or hyperlipidemia in patients suspected of developing arterial occlusive events interrupt or stop iclusig venous thromboembolism venous thromboembolic events occurred in   of iclusigtreated patients with an incidence rate of   cpcml   apcml   bpcml and   ph all events included deep venous thrombosis pulmonary embolism superficial thrombophlebitis and retinal vein thrombosis with vision loss consider dose modification or discontinuation of iclusig in patients who develop serious venous thromboembolism heart failure fatal or serious heart failure or left ventricular dysfunction occurred in  of iclusigtreated patients  nine percent of patients  experienced any grade of heart failure or left ventricular dysfunction the most frequently reported heart failure events were congestive cardiac failure and decreased ejection fraction  patients each  monitor patients for signs or symptoms consistent with heart failure and treat as clinically indicated including interruption of iclusig consider discontinuation if serious heart failure develops hepatotoxicity iclusig can cause hepatotoxicity including liver failure and death fulminant hepatic failure leading to death occurred in a patient within one week of starting iclusig two additional fatal cases of acute liver failure also occurred the fatal cases occurred in patients with bpcml or ph all severe hepatotoxicity occurred in all disease cohorts with   experiencing grade  or  hepatotoxicity the most common forms of hepatotoxicity were elevations of ast or alt  all grades  grade  or   not reversed at last followup bilirubin and alkaline phosphatase hepatotoxic events were observed in  of patients the median time to onset of hepatotoxicity event was  months monitor liver function tests at baseline then at least monthly or as clinically indicated interrupt reduce or discontinue iclusig as clinically indicated hypertension treatmentemergent elevation of systolic or diastolic blood pressure bp occurred in   of iclusigtreated patients fiftythree patients  experienced treatmentemergent symptomatic hypertension as a serious adverse reaction including hypertensive crisis patients may require urgent clinical intervention for hypertension associated with confusion headache chest pain or shortness of breath in patients with baseline systolic bp mm hg and baseline diastolic bp mm hg   experienced treatmentemergent hypertension   developed stage  hypertension  developed stage  hypertension in  patients with stage  hypertension at baseline   developed stage  hypertension monitor and manage blood pressure elevations during iclusig use and treat hypertension to normalize blood pressure interrupt dose reduce or stop iclusig if hypertension is not medically controlled in the event of significant worsening labile or treatmentresistant hypertension interrupt treatment and consider evaluating for renal artery stenosis pancreatitis pancreatitis occurred in    serious or grade  of iclusigtreated patients the incidence of treatmentemergent lipase elevation was   grade  or greater pancreatitis resulted in discontinuation or treatment interruption in  of patients  the median time to onset of pancreatitis was  days twentythree of the  cases of pancreatitis resolved within  weeks with dose interruption or reduction check serum lipase every  weeks for the first  months and then monthly thereafter or as clinically indicated consider additional serum lipase monitoring in patients with a history of pancreatitis or alcohol abuse dose interruption or reduction may be required in cases where lipase elevations are accompanied by abdominal symptoms interrupt treatment with iclusig and evaluate patients for pancreatitis do not consider restarting iclusig until patients have complete resolution of symptoms and lipase levels are less than  x uln increased toxicity in newly diagnosed chronic phase cml in a prospective randomized clinical trial in the firstline treatment of newly diagnosed patients with chronic phase cp cml single agent iclusig  mg oncedaily increased the risk of serious adverse reactions fold compared to single agent imatinib  mg oncedaily the median exposure to treatment was less than  months the trial was halted for safety in october  arterial and venous thrombosis and occlusions occurred at least twice as frequently in the iclusig arm compared to the imatinib arm compared to imatinibtreated patients iclusigtreated patients exhibited a greater incidence of myelosuppression pancreatitis hepatotoxicity cardiac failure hypertension and skin and subcutaneous tissue disorders iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed cpcml neuropathy peripheral and cranial neuropathy have occurred in iclusigtreated patients overall   of iclusigtreated patients experienced a peripheral neuropathy event of any grade  grade  the most common peripheral neuropathies reported were paresthesia   neuropathy peripheral   hypoesthesia   dysgeusia   muscular weakness   and hyperesthesia   cranial neuropathy developed in   of iclusigtreated patients    grade  of the patients who developed neuropathy   developed neuropathy during the first month of treatment monitor patients for symptoms of neuropathy such as hypoesthesia hyperesthesia paresthesia discomfort a burning sensation neuropathic pain or weakness consider interrupting iclusig and evaluate if neuropathy is suspected ocular toxicity serious ocular toxicities leading to blindness or blurred vision have occurred in iclusigtreated patients retinal toxicities including macular edema retinal vein occlusion and retinal hemorrhage occurred in  of iclusigtreated patients conjunctival irritation corneal erosion or abrasion dry eye conjunctivitis conjunctival hemorrhage hyperaemia and edema or eye pain occurred in  of patients visual blurring occurred in  of patients other ocular toxicities include cataracts periorbital edema blepharitis glaucoma eyelid edema ocular hyperaemia iritis iridocyclitis and ulcerative keratitis conduct comprehensive eye exams at baseline and periodically during treatment hemorrhage serious hemorrhage events including fatalities occurred in   of patients treated with iclusig hemorrhage occurred in   of patients the incidence of serious bleeding events was higher in patients with apcml bpcml and ph all gastrointestinal hemorrhage and subdural hematoma were the most commonly reported serious bleeding events occurring in   each most hemorrhagic events but not all occurred in patients with grade  thrombocytopenia interrupt iclusig for serious or severe hemorrhage and evaluate fluid retention fluid retention events judged as serious occurred in   of patients treated with iclusig one instance of brain edema was fatal for fluid retention events occurring in  of the patients treatmentemergent serious cases included pleural effusion   pericardial effusion   and edema peripheral   in total fluid retention occurred in  of the patients the most common fluid retention events were peripheral edema  pleural effusion  pericardial effusion  and peripheral swelling monitor patients for fluid retention and manage patients as clinically indicated interrupt reduce or discontinue iclusig as clinically indicated cardiac arrhythmias arrhythmias occurred in   of iclusigtreated patients of which   were grade  or greater arrhythmia of ventricular origin was reported in   of all arrhythmias with one case being grade  or greater symptomatic bradyarrhythmias that led to pacemaker implantation occurred in   of iclusigtreated patientsatrial fibrillation was the most common arrhythmia and occurred in   of patients approximately half of which were grade  or  other grade  or  arrhythmia events included syncope  patients  tachycardia and bradycardia  patients each  and electrocardiogram qt prolonged atrial flutter supraventricular tachycardia ventricular tachycardia atrial tachycardia atrioventricular block complete cardiorespiratory arrest loss of consciousness and sinus node dysfunction  patient each  for  patients the event led to hospitalizationin patients with signs and symptoms suggestive of slow heart rate fainting dizziness or rapid heart rate chest pain palpitations or dizziness interrupt iclusig and evaluate myelosuppression myelosuppression was reported as an adverse reaction in   of iclusigtreated patients and grade  myelosuppression occurred in   of patients the incidence of these events was greater in patients with apcml bpcml and ph all than in patients with cpcmlsevere myelosuppression grade  or  was observed early in treatment with a median onset time of  month range  months obtain complete blood counts every  weeks for the first  months and then monthly or as clinically indicated and adjust the dose as recommended tumor lysis syndrome two patients  one with apcml and one with bpcml treated with iclusig developed serious tumor lysis syndrome hyperuricemia occurred in   of patients due to the potential for tumor lysis syndrome in patients with advanced disease ensure adequate hydration and treat high uric acid levels prior to initiating therapy with iclusig reversible posterior leukoencephalopathy syndrome rpls postmarketing cases of reversible posterior leukoencephalopathy syndrome rpls—also known as posterior reversible encephalopathy syndrome pres have been reported in iclusigtreated patients rpls is a neurological disorder that can present with signs and symptoms such as seizure headache decreased alertness altered mental functioning vision loss and other visual and neurological disturbances hypertension is often present and diagnosis is made with supportive findings on magnetic resonance imaging mri of the brain if rpls is diagnosed interrupt iclusig treatment and resume treatment only once the event is resolved and if the benefit of continued treatment outweighs the risk of rpls compromised wound healing and gastrointestinal perforation since iclusig may compromise wound healing interrupt iclusig for at least  week prior to major surgery serious gastrointestinal perforation fistula occurred in one patient  days postcholecystectomy embryofetal toxicity based on its mechanism of action and findings from animal studies iclusig can cause fetal harm when administered to a pregnant woman in animal reproduction studies oral administration of ponatinib to pregnant rats during organogenesis caused adverse developmental effects at exposures lower than human exposures at the recommended human dose advise pregnant women of the potential risk to the fetus advise females of reproductive potential to use effective contraception during treatment with iclusig and for  weeks after the last dose most common adverse reactions overall the most common nonhematologic adverse reactions ≥ were abdominal pain rash constipation headache dry skin fatigue hypertension pyrexia arthralgia nausea diarrhea lipase increased vomiting myalgia and pain in extremity hematologic adverse reactions included thrombocytopenia anemia neutropenia lymphopenia and leukopenia please see the full us prescribing information for iclusig including the boxed warningiclusig is a registered trademark of ariad pharmaceuticals inc   additional information the tender offer described in this press release has not yet commenced this press release is provided for informational purposes only and does not constitute an offer to purchase or the solicitation of an offer to sell any securities at the time the tender offer is commenced takeda and its wholly owned subsidiary kiku merger co inc intend to file with the securities and exchange commission the “sec” a tender offer statement on schedule to containing an offer to purchase a form of letter of transmittal and other documents relating to the tender offer and ariad intends to file with the sec a solicitationrecommendation statement on schedule d  with respect to the tender offer takeda kiku merger co inc and ariad intend to mail these documents to the ariad stockholders investors and shareholders should read those filings carefully when they become available as they will contain important information about the tender offer those documents may be obtained without charge at the sec’s website at wwwsecgov the offer to purchase and related materials may also be obtained when available for free by contacting the information agent for the tender offer cautionary statement regarding forwardlooking statements this press release contains forwardlooking information related to takeda ariad and the proposed acquisition of ariad by takeda that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements forwardlooking statements in this document include among other things statements about the potential benefits of the proposed acquisition anticipated earnings accretion and growth rates takeda’s and ariad’s plans objectives expectations and intentions the financial condition results of operations and business of takeda and ariad ariad’s products ariad’s pipeline assets and the anticipated timing of closing of the acquisition risks and uncertainties include among other things risks related to the satisfaction of the conditions to closing the acquisition including the failure to obtain necessary regulatory approvals in the anticipated timeframe or at all including uncertainties as to how many of ariad’s stockholders will tender their shares in the tender offer and the possibility that the acquisition does not close risks related to the ability to realize the anticipated benefits of the acquisition including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period the risk that the businesses will not be integrated successfully disruption from the transaction making it more difficult to maintain business and operational relationships negative effects of this announcement or the consummation of the proposed acquisition on the market price of takeda’s common stock and on takeda’s operating results significant transaction costs unknown liabilities the risk of litigation andor regulatory actions related to the proposed acquisition other business effects including the effects of industry market economic political or regulatory conditions future exchange and interest rates changes in tax and other laws regulations rates and policies future business combinations or disposals the uncertainties inherent in research and development including the ability to sustain and increase the rate of growth in revenues for ariad’s products despite increasing competitive reimbursement and economic challenges whether and when any drug applications may be filed in any jurisdictions for any indications or any additional indications for ariad’s products or for ariad’s pipeline assets whether and when the fda or any other applicable regulatory authorities may approve any such applications which will depend on its assessment of the benefitrisk profile suggested by the totality of the efficacy and safety information submitted decisions by the fda or other regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of ariad’s products and ariad’s pipeline assets and competitive developments many of these factors are beyond takeda’s control unless otherwise required by applicable law takeda disclaims any intention or obligation to update forwardlooking statements contained in this document as the result of new information or future events or developments    copyright  takeda pharmaceutical company limited all rights reserved we use cookies to gather web statistics that help us improve our site we store no personal details accept read more microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft health care professionals information  alunbrig brigatinib for healthcare professionals this site is intended for us healthcare professionals only now approved introducing alunbrig™—a new treatment for patients with anaplastic lymphoma kinase alkpositive metastatic nonsmall cell lung cancer nsclc who have progressed on or are intolerant to crizotinib this indication is approved under accelerated approval based on tumor response rate and duration of response continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial   in the news learn more about the fda approval of alunbrig view press release patient support alunbrig point can support your patients throughout the course of their therapy access a patient access specialist can work with your patient and your office to conduct a benefits investigation and provide you both with details on your patients drug coverage and options afford regardless of your patients insurance status alunbrig point can help identify an array of financial assistance programs for which they may be eligible assist alunbrig point is committed to supporting your patients throughout their treatment by offering a wide range of services to get them the information they need and assist with daytoday concerns associated with their treatment find out more important resources for your practice download dosing guide stay connected stay informed about alunbrig—sign up to be notified about product and news updates required fields first name please enter your first name last name please enter your last name email address please enter your email please select your specialty select oncology radiology internal medicine other physician nursing pharmacy other hcp please select your specialty i would like to receive updates about alunbrig using the contact information i provided above check this box to confirm that you agree to takeda’s privacy policy and terms and conditions and that takeda or companies working with takeda may send you information about lung cancer takeda products and services and other healthrelated topics using the contact information you provided above please confirm that you accept our privacy policy and terms and conditions submit you have successfully registered thank you for registering you will hear from us when we have updates alunbrig product information overviewalunbrig dosage andadministration efficacyand safety summary please read full prescribing information for alunbrig important safety information warnings and precautions interstitial lung disease ildpneumonitis severe lifethreatening and fatal pulmonary adverse reactions consistent with interstitial lung disease ildpneumonitis have occurred with alunbrig in trial alta alta ildpneumonitis occurred in  of patients in the  mg group  mg once daily and  of patients in the → mg group  mg once daily with day leadin at  mg once daily adverse reactions consistent with possible ildpneumonitis occurred early within  days of initiation of alunbrig median onset was  days in  of patients with grade  to  reactions occurring in  monitor for new or worsening respiratory symptoms eg dyspnea cough etc particularly during the first week of initiating alunbrig withhold alunbrig in any patient with new or worsening respiratory symptoms and promptly evaluate for ildpneumonitis or other causes of respiratory symptoms eg pulmonary embolism tumor progression and infectious pneumonia for grade  or  ildpneumonitis either resume alunbrig with dose reduction after recovery to baseline or permanently discontinue alunbrig permanently discontinue alunbrig for grade  or  ildpneumonitis or recurrence of grade  or  ildpneumonitis hypertension in alta hypertension was reported in  of patients in the  mg group who received alunbrig and  of patients in the → mg group grade  hypertension occurred in  of patients overall control blood pressure prior to treatment with alunbrig monitor blood pressure after  weeks and at least monthly thereafter during treatment with alunbrig withhold alunbrig for grade  hypertension despite optimal antihypertensive therapy upon resolution or improvement to grade  severity resume alunbrig at a reduced dose consider permanent discontinuation of treatment with alunbrig for grade  hypertension or recurrence of grade  hypertension use caution when administering alunbrig in combination with antihypertensive agents that cause bradycardia bradycardia bradycardia can occur with alunbrig in alta heart rates less than  beats per minute bpm occurred in  of patients in the  mg group and  of patients in the → mg group grade  bradycardia occurred in   patient in the  mg group monitor heart rate and blood pressure during treatment with alunbrig monitor patients more frequently if concomitant use of drug known to cause bradycardia cannot be avoided for symptomatic bradycardia withhold alunbrig and review concomitant medications for those known to cause bradycardia if a concomitant medication known to cause bradycardia is identified and discontinued or dose adjusted resume alunbrig at the same dose following resolution of symptomatic bradycardia otherwise reduce the dose of alunbrig following resolution of symptomatic bradycardia discontinue alunbrig for lifethreatening bradycardia if no contributing concomitant medication is identified visual disturbance in alta adverse reactions leading to visual disturbance including blurred vision diplopia and reduced visual acuity were reported in  of patients treated with alunbrig in the  mg group and  of patients in the → mg group grade  macular edema and cataract occurred in one patient each in the → mg group advise patients to report any visual symptoms withhold alunbrig and obtain an ophthalmologic evaluation in patients with new or worsening visual symptoms of grade  or greater severity upon recovery of grade  or grade  visual disturbances to grade  severity or baseline resume alunbrig at a reduced dose permanently discontinue treatment with alunbrig for grade  visual disturbances creatine phosphokinase cpk elevation in alta creatine phosphokinase cpk elevation occurred in  of patients receiving alunbrig in the  mg group and  of patients in the  mg→ mg group the incidence of grade  cpk elevation was  in the  mg group and  in the → mg group dose reduction for cpk elevation occurred in  of patients in the  mg group and  in the → mg group advise patients to report any unexplained muscle pain tenderness or weakness monitor cpk levels during alunbrig treatment withhold alunbrig for grade  or  cpk elevation upon resolution or recovery to grade  or baseline resume alunbrig at the same dose or at a reduced dose pancreatic enzyme elevation in alta amylase elevation occurred in  of patients in the  mg group and  of patients in the → mg group lipase elevations occurred in  of patients in the  mg group and  of patients in the → mg group grade  or  amylase elevation occurred in  of patients in the  mg group and  of patients in the → mg group grade  or  lipase elevation occurred in  of patients in the  mg group and  of patients in the → mg group monitor lipase and amylase during treatment with alunbrig withhold alunbrig for grade  or  pancreatic enzyme elevation upon resolution or recovery to grade  or baseline resume alunbrig at the same dose or at a reduced dose hyperglycemia in alta  of patients who received alunbrig experienced new or worsening hyperglycemia grade  hyperglycemia based on laboratory assessment of serum fasting glucose levels occurred in  of patients two of   patients with diabetes or glucose intolerance at baseline required initiation of insulin while receiving alunbrig assess fasting serum glucose prior to initiation of alunbrig and monitor periodically thereafter initiate or optimize antihyperglycemic medications as needed if adequate hyperglycemic control cannot be achieved with optimal medical management withhold alunbrig until adequate hyperglycemic control is achieved and consider reducing the dose of alunbrig or permanently discontinuing alunbrig embryofetal toxicity based on its mechanism of action and findings in animals alunbrig can cause fetal harm when administered to pregnant women there are no clinical data on the use of alunbrig in pregnant women advise pregnant women of the potential risk to a fetus advise females of reproductive potential to use effective nonhormonal contraception during treatment with alunbrig and for at least  months following the final dose advise males with female partners of reproductive potential to use effective contraception during treatment and for at least  months after the last dose of alunbrig adverse reactions serious adverse reactions occurred in  of patients in the  mg group and  of patients in the → mg group the most common serious adverse reactions were pneumonia  overall  in the  mg group and  in the → mg group and ildpneumonitis  overall  in the  mg group and  in the → mg group fatal adverse reactions occurred in  of patients and consisted of pneumonia  patients sudden death dyspnea respiratory failure pulmonary embolism bacterial meningitis and urosepsis  patient each the most common adverse reactions ≥ in the  mg group were nausea  fatigue  headache  and dyspnea  and in the → mg group were nausea  diarrhea  fatigue  cough  and headache  drug interactions cypa inhibitors avoid concomitant use of alunbrig with strong cypa inhibitors avoid grapefruit or grapefruit juice as it may also increase plasma concentrations of brigatinib if concomitant use of a strong cypa inhibitor is unavoidable reduce the dose of alunbrig cypa inducers avoid concomitant use of alunbrig with strong cypa inducers cypa substrates coadministration of alunbrig with cypa substrates including hormonal contraceptives can result in decreased concentrations and loss of efficacy of cypa substrates use in specific populations pregnancy alunbrig can cause fetal harm advise females of reproductive potential of the potential risk to a fetus lactation advise lactating women not to breastfeed during treatment with alunbrig and for  week following the final dose females and males of reproductive potential contraception advise females of reproductive potential to use effective nonhormonal contraception during treatment with alunbrig and for at least  months after the final dose advise males with female partners of reproductive potential to use effective contraception during treatment with alunbrig and for at least  months after the final dose infertility alunbrig may cause reduced fertility in males pediatric use the safety and efficacy of alunbrig in pediatric patients have not been established geriatric use clinical studies of alunbrig did not include sufficient numbers of patients aged  years and older to determine whether they respond differently from younger patients of the  patients in alta  were  years and  were  years or older no clinically relevant differences in safety or efficacy were observed between patients ≥ and younger patients hepatic or renal impairment no dose adjustment is recommended for patients with mild hepatic impairment or mild or moderate renal impairment the safety of alunbrig in patients with moderate or severe hepatic impairment or severe renal impairment has not been studied you may report side effects to the fda at fda or wwwfdagovmedwatch you may also report side effects directly to takeda oncology at apoint  or medinfoariadcom please read full prescribing information for alunbrig   you are now leaving alunbrigcom the official site for alunbrig™ brigatinib this link will take you to the corporate takeda oncology website continue cancel you are now leaving alunbrigcom the official site for alunbrig™ brigatinib this link will take you to the alunbrig point™ website continue cancel you are now leaving alunbrigcom the official site for alunbrig™ brigatinib this link will take you to the fda website continue cancel the site you are about to enter is intended for us healthcare professionals only please confirm that you are a us healthcare professional yes i confirm that i am a us healthcare professional cancel ariad pharmaceuticals  office in cambridge foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingplanning a trip to bostonfoursquare can help you find the best places to go tofind great things to doariad pharmaceuticalsofficecambridgesavesharetips photos ariad pharmaceuticals tip and reviewlog in to leave a tip herepostkristine nardelliapril  been here  timessola flour bytes thailand cafe and miracle of science are great places to eat lunch photorelated searchesariad pharmaceuticals cambridge  ariad pharmaceuticals cambridge photos  ariad pharmaceuticals cambridge location  ariad pharmaceuticals cambridge address  ariad pharmaceuticals cambridge  ariad pharmaceuticals cambridge  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeyfoursquare    lovingly made in nyc  sfariad pharmaceuticals landsdowne stcambridge ma united statesget directions none listed see when people check inpeople tend to check in during these timestoday am– pm pm– pmwed am– pmthu–fri am– pmsat–sunnonemon am– pmsee moreis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around youariad pharmaceuticals  office in cambridge foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingplanning a trip to bostonfoursquare can help you find the best places to go tofind great things to doariad pharmaceuticalsofficecambridgesavesharetips photos ariad pharmaceuticals tip and reviewlog in to leave a tip herepostkristine nardelliapril  been here  timessola flour bytes thailand cafe and miracle of science are great places to eat lunch photorelated searchesariad pharmaceuticals cambridge  ariad pharmaceuticals cambridge photos  ariad pharmaceuticals cambridge location  ariad pharmaceuticals cambridge address  ariad pharmaceuticals cambridge  ariad pharmaceuticals cambridge  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeyfoursquare    lovingly made in nyc  sfariad pharmaceuticals landsdowne stcambridge ma united statesget directions none listed see when people check inpeople tend to check in during these timestoday am– pm pm– pmwed am– pmthu–fri am– pmsat–sunnonemon am– pmsee moreis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around youkristines tip at ariad pharmaceuticals foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingplanning a trip to bostonfoursquare can help you find the best places to go tofind great things to doariad pharmaceuticalsofficecambridgesavesharetips photos ariad pharmaceuticals tip and reviewlog in to leave a tip herepostkristine nardelliapril  been here  timessola flour bytes thailand cafe and miracle of science are great places to eat lunch photorelated searchesariad pharmaceuticals cambridge  ariad pharmaceuticals cambridge photos  ariad pharmaceuticals cambridge location  ariad pharmaceuticals cambridge address  ariad pharmaceuticals cambridge  ariad pharmaceuticals cambridge  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeyfoursquare    lovingly made in nyc  sfariad pharmaceuticals landsdowne stcambridge ma united statesget directions none listed see when people check inpeople tend to check in during these timestoday am– pm pm– pmwed am– pmthu–fri am– pmsat–sunnonemon am– pmsee moreis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around youariad pharmaceuticals  office in cambridge foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingplanning a trip to bostonfoursquare can help you find the best places to go tofind great things to doariad pharmaceuticalsofficecambridgesavesharetips photos ariad pharmaceuticals tip and reviewlog in to leave a tip herepostkristine nardelliapril  been here  timessola flour bytes thailand cafe and miracle of science are great places to eat lunch photorelated searchesariad pharmaceuticals cambridge  ariad pharmaceuticals cambridge photos  ariad pharmaceuticals cambridge location  ariad pharmaceuticals cambridge address  ariad pharmaceuticals cambridge  ariad pharmaceuticals cambridge  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeyfoursquare    lovingly made in nyc  sfariad pharmaceuticals landsdowne stcambridge ma united statesget directions none listed see when people check inpeople tend to check in during these timestoday am– pm pm– pmwed am– pmthu–fri am– pmsat–sunnonemon am– pmsee moreis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around you yelp yelp sorry you’re not allowed to access this page contact yelp if you keep experiencing issues bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft robot check enter the characters you see below sorry we just need to make sure youre not a robot for best results please make sure your browser is accepting cookies type the characters you see in this image try different image continue shopping conditions of use privacy policy   amazoncom inc or its affiliates search engine marketing sem  bing ads skip to content sign upsign in   you run your business well help find your customers bing ads can help build your business and drive your success spend  and get  in advertising credit† †offer details get  in search advertising when you spend  in bing ads coupon code class first name last name email your website url business phone required microsoft may contact you to provide updates and special offers about bing ads you can unsubscribe at any time to learn more you can read the privacy statement type the code from the image enter security code   × get  in search advertising when you spend  in bing ads †offer details offer expires december   valid only for new bing ads customers who are first party recipients of the offer email a new bing ads customer is one that has not advertised on bing ads before enter promotional coupon code and spend  applies to threshold and prepaid accounts to receive  in bing ads credits limit one promotion code per new bing ads customer promotional code must be redeemed within thirty  days of bing ads new customer account creation ad campaign costs accrued before receiving a credit as well as costs accrued after all credits are used will be charged to the payment method associated with the bing ads account if customer payment fails the coupon amount will not be applied ads will continue to run and accrue costs after any promotional credit has been used up any portion of the credit not used within ninety  days of credit redemption will expire and cant be carried over even if the bing ads customer switches their payment method offer valid only to residents of the united states in order for the offer to be valid a form of payment must be entered into your account prior to redemption of the promotional code and prior to your account going live to take advantage of the credit this offer may not be combined with any other offer promotional code coupon or discount separated redeemed for cash transferred sold or bartered microsoft in its sole discretion can close your account for any suspected coupon abuse refund of the  is not permitted see bing ads terms and conditions for more details at signup other terms and conditions may apply microsoft reserves the right to cancel change or suspend this offer at any time without notice see how bing ads works customers search customers see your ad customers contact you watch how bing ads works     × how bing ads works help more customers find you see how bing can attract customers your google adwords campaigns cant reach  million searchers on the bing network tap into  of the search marketplace get in front of searchers who spend  percent more than the average internet searcher powerful network powerful benefits reach across devicesconnect with customers looking for your business anytime anywhere on any device go global or localreach people in the bing network everywhere or focus on cities counties and areas within a certain distance from your business easy to importif youre already using another product like google adwords its easy to pull that campaign into bing ads you control your costs  free signupjoin bing ads for free and control your account at every step  only pay for clickspay just when customers click on your ad no click no charge  no minimum feestart advertising with a budget that works best for your business   the advantage we gain in cost per click gives us a great return on investment — more than  percent better than google adwords scott redgate search engine marketing manager — cj pony parts by using bing ads features like image extensions and sitelink extensions this auto parts retailer races to convert customers and beat its competition  read about driving more conversions   we might not get as much of the volume as with google adwords but the volume of the traffic that we get converts really well at a lower cost scott schult executive vice president of marketing — myrtle beach area convention and visitors bureau the myrtle beach area convention and visitors bureau uses bing ads to drive site traffic and tourism at lower cost  read about getting better roi better results for less cost thats as simple as i can make it if i look at the quality of the traffic we get for the dollars we spend on bing ads our roi is fantastic alex littlewood ceo   motoroso motoroso a market network for auto enthusiasts gets better results for less cost and reaches a highvalue audience with bing ads  read about attracting quality traffic   import your adwords campaigns save time by importing your google adwords campaigns into bing ads to get ads live quickly sign in with your microsoft account or create one to get started on bing ads from within the bing ads interface select the import from google adwords option enter your google adwords credentials and select the campaign you want to import preview your ad get found online with search engine marketing make the most of your marketing dollars and drive customers to your business see how bing ads can work for you get started today give us a few details about your business to create a bing ads account and get it up and running   sign up get started with bing ads signing up is always free faq is bing ads right for me is bing ads right for my business all types of businesses find value and success with bing ads whether youre focused on local calls and foot traffic or want to drive traffic to your website from across the country or around the world bing ads has solutions for you i already appear in search results for free why should i pay for advertising your current customers may search for your business by name aiming it easy to find you in search results but customers youve yet to reach are more likely searching for general terms that wouldnt necessarily bring up your business in search results advertising next to relevant bing search results puts your business front and center with interested customers you otherwise might not reach what is the difference between seo and sem which one is right for me search engine optimization seo is adjusting your website to improve your natural ranking in search results you cannot pay to improve your website ranking on bing or yahoo thus we often refer to these results and unpaid or organic search results clicks from seo are free but seo also requires technical expertise and involves some factors over which you have only limited control search engine marketing sem is paid advertising that appears next to or above unpaid or organic search results these paid ads are purchased through bing ads you pay for sem clicks but sem gives you more control over when your website appears on results pages and you decide how much you want to pay and you can measure which ads are working and quickly improve your results you dont have to choose between seo and sem you can do both if my time is limited should i still try bing ads yes call a bing ads specialist at and we’ll set up your first campaign for you for free we’ll give you tips on getting the most out of your ads and set you up for success we’re here to help about bing ads where does my ad appear your ads could appear on the top or to the right of bing yahoo and msn search results and you can choose to target your ads to different geographic regions times or days of the week and even demographics what determines my ad position bing ads is a payperclick ppc advertising system you bid based on how much you are willing to pay per each click on your ad because webpages have a limited number of places to show ads we auction those spaces you are bidding against other advertisers to get your ads into the space you want so if you bid on the keyword shoe you will have to beat the bids of the other advertisers who are also bidding on shoe you determine how much you are willing to bid your ad position is based on several things including how closely your ad and website fit with the terms that are searched relevance how your bid compares to other bids in the bing ads auction how strongly your ad has performed in the past and how often it has been clicked clickthrough rate the stronger you are in these areas the better your chances of winning the top ad position how to use bing ads how can i use bing ads to drive more people to my website here are some tips to get better results review your budget and bid strategy if your ad keeps pausing your budget limit may be set too low competitive bids help your ad stay in a strong position to catch eyes and get more clicks to your website expand your targeting both for location and for devices computer mobile and tablet make sure your ads and website are relevant to the keywords you bid on would someone searching your terms expect to see and ad for your business how can i keep my costs down while your first instinct may be to lower your budget first try lowering your maximum bids yes this could mean fewer customers visit your site but if you increase your quality score and build ads with a strong performance history you may be able to win a good ad position with a lower bid that would lower your costperclick and help stretch your budget how do i know if bing ads is working view a wide range of performance trends in your account to quickly see key stats ad clicks the number of times your ad appeared impressions spend average costperclick clickthrough rate average ad position cost per acquisition and conversions you can also run performance reports to get insights into how well your campaigns are doing can i run more than one ad yes in fact we encourage it only one ad will show at a time but running multiple ads lets you test different approaches to see whats working best with your target customers frequently businesses try out different ads for specific products or pages getting started with bing ads how do i get started sign up for bing ads which keywords should i choose you have a few options to help choose your keywords first youll want to think of the terms one of your customers might use to search for your products and offerings those search terms are a great starting point then you can use tools right in your account to find more keywords within bing ads click campaigns on the top of the page click the keywords tab and then click add keywords this will let you search for new keywords based on one you enter search a website for keywords search your destination urls for keywords how can i write a good ad here are a few tips that can help make your ad stand out keep your ads relevant one way to improve relevance is to use your customers most popular search terms in your ad titles and txt describe what sets your product apart use your customers language use words and writing tone that are likely to attract your typical customer be specific this clearer and more specific your offering the better for example rather than big discount specify and exact percentage such as  percent off give customers a reason to click your ad right now offer a specific call to action such as encouraging customers to request a brochure or consultation download a free ebook subscribe to a newsletter or take advantage of a limitedtime discount sign up with bing ads to get started